US Pat. No. 10,888,508

MULTI-FUNCTIONAL COOLANT FOR DENTISTRY USE

1. A multifunctional dental coolant comprising, based on a batch having a total volume of 1000 cc:1.07 g polyoxyethylene sorbitan monooleate;
3.93 g sorbitan monooleate;
0.05M ethylene diamine tetra acetic acid (EDTA);
0.025 g sodium benzoate; and
distilled water in a volume sufficient for reaching the total volume of 1000 cc.
US Pat. No. 10,889,790

GROWTH OF BACTERIAL HOST CELLS IN GAS PERMEABLE LOW-DENSITY POLYETHYLENE BAGS FOR PRODUCTION OF PLASMID DNA OR RECOMBINANT MOLECULES

ALDEVRON, LLC, Fargo, ND...

1. A method of growing bacterial host cells in a gas-permeable bag comprising the steps of:providing a starter culture of bacterial host cells, wherein the starter culture comprises at least one colony of the host cells transformed with plasmids comprising an antibiotic resistance gene;
providing the gas-permeable bag;
adding media, an antibiotic, and the starter culture host cells to the gas-permeable bag to form a main culture, wherein the antibiotic is selected such that starter culture host cells expressing the antibiotic resistance gene are viable in the presence of the antibiotic; and
incubating the gas-permeable bag containing the main culture such that host cells grow to a desired concentration.
US Pat. No. 10,889,792

CELL EXPANSION VESSEL SYSTEMS AND METHODS

Global Life Sciences Solu...

1. A method, comprising:introducing a suspension comprising cells suspended in a cell culture medium through at least a feed port or a drain port into a cavity of a cell culture vessel, the suspension being in an amount sufficient to cover a gas permeable, liquid impermeable membrane positioned at a bottom of the cell culture vessel, the feed port configured to permit additional cell culture, medium into the cavity, and the drain port configured to permit removal of the cells, cell culture medium, and used cell culture medium from the cavity;
allowing the cells to settle on the gas permeable, liquid impermeable membrane by gavity;
perfusing the cells with the cell culture medium, wherein the perfusing comprises
removing the used cell culture medium through the drain port and introducing the additional cell culture medium through the feed port such that a constant volume is maintained in the cell culture vessel until the cells expand to a desired density, wherein the removing and introducing are performed subsequent to allowing the cells to settle on the gas permeable, liquid impermeable membrane;
resuspending the cells in the cell culture medium in the cell culture vessel, wherein the resuspending is performed after the desired cell density is attained; and
removing the resuspended cells and the cell culture medium through the drain port.
US Pat. No. 10,888,511

METHODS AND ARTICLES OF MANUFACTURE FOR THE TREATMENT OF SKIN

Advanced Collagen Science...

1. A method of treating dermis in vivo comprising the steps of:topically pretreating an area of skin in a subject with dermal abrasion and with one or more penetration devices configured to ablate or puncture stratum corneum and epithelium, wherein the one or more penetration devices comprise microneedles;
further topically pretreating the exposed tissue surface with alkaline buffer solution for 30 seconds to 2 minutes to bring the pH of the tissue surface to between 7.5 and 9.5; and
topically applying to said area of skin an effective amount of an acylation agent to increase one or more skin characteristics consisting of at least one selected from the group consisting of: hydration, pliability and thickness, wherein the acylation agent is selected from the group consisting of: glutaric anhydride, succinic anhydride, methyl glutaric anhydride, maleic anhydride, pthalic anhydride, and mixtures and combinations thereof.
US Pat. No. 10,888,512

THICKENING SYSTEM FOR A PERCARBONATE-CONTAINING COLOUR COMPOSITION AND STORAGE IN A MULTILAYER SACHET

1. A cosmetic product for changing the natural colour of keratinous fibres, comprising:(i) at least one package (VP), comprising at least one multilayer film (F), which comprises at least one first polymer layer (P1), at least one second polymer layer (P2), and at least one barrier layer (BS), and
(ii) at least one cosmetic composition (KM), which is packaged in the package (VP) and comprises:
a) at least one oxidizing compound, and
b) at least one thickening agent, and
(iii) at least one cosmetic colour composition (FZ), which is packaged in the package (VP),
wherein the oxidizing compound is a solid oxidizing agent.
US Pat. No. 10,888,513

PERSONAL CLEANSING COMPOSITIONS

Conopeo, Inc., Englewood...

1. A personal cleansing composition comprising:(i) an aqueous continuous phase comprising sodium lauryl ether sulphate (nEO) in which n ranges from 1 to 3.5;
(ii) one or more oily liquid conditioning agents for skin and/or hair wherein the one or more agents are solubilized in wormlike micelles in the aqueous continuous phase via the incorporation of at least one inorganic electrolyte and at least one linker molecule, wherein the one or more oily liquid conditioning agents are light mineral oils, and the at least one linker molecule is selected from the group consisting of alkyl or aromatic carboxylic acid, alkyl or aromatic alcohol, C8-C22 alkyl ethoxy alcohol, C1-C3 alkyl esters of fatty acids, carboxyl amino acid, and a combination of two or more thereof;
(iii) one or more cationic polygalactomannans having a mean charge density at pH 7 from 0.2 to 2 meq per gram, wherein the one or more cationic polygalactomannans comprise guar hydroxypropyltrimethylammonium chlorides; and
(iv) a homopolymer of (3-acrylamidopropyl) trimethyl ammonium chloride;
wherein the composition comprises 10 wt % to 14 wt % of the sodium lauryl ether sulfate, 0.5 wt % to 1.5 wt % of the one or more oily liquid conditioning agents, 0.05 wt % to 0.25 wt % of the one or more cationic polygalactomannans, and 0.2 wt % to 1.5 wt % of the homopolymer of (3-acrylamidopropyl) trimethyl ammonium chloride, based on the total weight of the composition.
US Pat. No. 10,888,514

COSMETIC COMPOSITIONS

1. A cosmetic composition, comprising:about 40 to about 75% by weight of a silicone oil comprising dimethicone;
more than about 6% by weight of a spherical powder comprising amorphous silica;
about 0.5 to about 20% by weight of a pigment comprising iron oxide, titanium dioxide and combinations thereof;
about 1 to about 5% by weight of silicone emulsifier comprising PEG-10 dimethicone;
about 0.25 to about 5% by weight of hydrophobic silica particles comprising silica silylate; and
about 0.25 to about 5% by weight of a silicone resin comprising trimethylsiloxysilicate,
wherein the cosmetic composition is anhydrous.
US Pat. No. 10,889,540

PREPARATION METHOD OF A FORMAMIDE COMPOUND

BEIJING J-TEC TECHNOLOGY ...

1. A preparation method of formamide compound, consisting of steps of:mixing raw materials of methanoic acid and an amine compound selected from a primary amine or a secondary amine to prepare a homogeneous reaction system;
heating the homogeneous reaction system in a high-pressure reactor to 160° C. or higher, keeping temperature for a period of time, then continuing to heat the homogeneous reaction system to react until a pressure in the high-pressure reactor rises to 1.0-3.0 MPa and no higher, keeping reaction for 1-5 hours, and collecting reaction product to obtain the formamide compound.
US Pat. No. 10,888,515

PRODUCING A TOPICAL SOLUTION COMPOSITION

Shantel Medical Supply Co...

1. A method of producing a topical solution composition, the method comprising:providing a grape extract, wherein the grape extract comprises resveratrol;
adding an aqueous solution with an emulsifier to the grape extract;
mixing the grape extract and aqueous solution with the emulsifier, obtaining a topical solution composition; and
adding vitamins to the topical solution composition in an amount sufficient to increase the pH of the topical solution composition to be within a range of from 2.5 to 5.5.
US Pat. No. 10,889,797

THREE PHASE PARTITIONING (TPP) METHOD FOR VIRUS PURIFICATION

Virovek Incorporation, H...

1. A method of purifying an adeno-associated virus from a baculovirus-infected cell lysate, the method comprising:a) forming a first mixture comprising i) an aqueous phase comprising water and a cell lysate comprising an adeno-associated virus, ii) t-butanol, and iii) ammonium sulfate at a first concentration;
b) separating the first mixture to form a first organic phase, a first interphase, and a first aqueous phase; and
c) collecting the first aqueous phase, wherein the ammonium sulfate at a first concentration is ammonium sulfate at a concentration at which t-butanol is immiscible with water.
US Pat. No. 10,888,516

SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION

TherapeuticsMD, Inc., Bo...

1. A method of treating a symptom of vulvovaginal atrophy in a female human patient in need thereof, the method comprising administering to the female human an estradiol-containing soft gelatin capsule intravaginally once daily for 14 days and one capsule twice weekly thereafter, the estradiol-containing soft gelatin capsule comprising a gelatin shell surrounding an estradiol-containing liquid fill material, the estradiol-containing liquid fill material comprising one or more C6 to C14 fatty acid mono-, di-, or triesters of glycerol and 1 to 10 mcg of estradiol, wherein the estradiol-containing liquid fill material has a viscosity of between 50 to 1000 cP as measured at 25° C.wherein:
administering the estradiol-containing soft gelatin capsule intravaginally to the female human in need thereof provides an estradiol AUC and estradiol Cmax that are each 80% to 125% of the estradiol AUC and estradiol Cmax obtained upon intravaginal administration of a reference soft gelatin capsule in a reference human female patient, the reference soft gelatin capsule consisting of a soft gelatin shell and a reference liquid fill material within the soft gelatin shell, wherein the reference liquid fill material consists of
approximately 270 mg of a C8 to C10 triglyceride composition containing at least about 80 percent by weight of a mixture of caprylic acid and capric acid;
approximately 30 mg of a surfactant containing a mixture of PEG-6 stearate, PEG-32 stearate, and ethylene glycol palmitostearate; and
1 to 10 mcg of estradiol
further wherein the reference liquid fill material has a viscosity of between 50 to 1000 cP as measured at 25° C.
US Pat. No. 10,889,798

STABLE FUNGAL BLASTOSPORES AND METHODS FOR THEIR PRODUCTION, STABILIZATION AND USE

The United States of Amer...

1. An insecticidal composition, comprising an agronomically acceptable carrier and desiccation-tolerant blastospores of Beauveria bassiana with greater than 60% germination when rehydrated and grown in a suitable medium after storage for more than six months at 4° C., wherein said carrier and said blastospores are contained in air-tight packaging and wherein said blastospores are produced by a method comprising the steps of:a) inoculating a liquid culture medium comprising a carbon source and a nitrogen source with fungal propagules of Beauveria basianna, wherein said nitrogen source is present in said liquid culture medium at an initial concentration of at least 1.5% (w/v);
b) incubating said propagules under liquid culture conditions providing dissolved oxygen levels above zero and osmotic pressure greater than 0.5 MPa;
c) incubating said propagules in said liquid culture for a sufficient time to produce blastospores;
d) collecting said blastospores; and
e) drying said blastospores, thereby producing desiccation-tolerant blastospores.
US Pat. No. 10,888,517

THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE

Rani Therapeutics, LLC, ...

1. A method for delivering PTH or PTH analogue to a patient in need thereof, the method comprising:providing a swallowable enclosure having an interior, a delivery means, and a PTH or PTH analogue preparation coupled to the delivery means, the PTH or PTH analogue preparation comprising a therapeutically effective dose of PTH or PTH analogue, the delivery means having a first configuration and a second configuration, the preparation being contained within the interior in the first configuration and advanced out of the interior and into a gastro-intestinal (GI) lumen wall in the second configuration so as to deliver the PTH or PTH analogue preparation into the GI lumen wall, the enclosure protecting the PTH or PTH analogue preparation from degradation by GI fluids, the PTH or PTH analogue preparation supplied in the enclosure in a form which can be delivered from the enclosure into the GI lumen wall by the application of force on the preparation; and
triggering the delivery means within the GI lumen responsive to a condition in the lumen to deliver the PTH or PTH analogue preparation from the enclosure into the GI lumen wall, wherein the dose of PTH or PTH analogue is released into the patient's blood stream.
US Pat. No. 10,889,799

METHODS OF MAKING SPHEROIDS INCLUDING BIOLOGICALLY-RELEVANT MATERIALS

University of Louisville ...

1. A method of making a spheroid comprising one or more biologically-relevant materials, the method comprising:providing a droplet of a suspension on a delivery pen tip, wherein the suspension comprises one or more biologically-relevant materials dispersed within a biocompatible medium;
bringing the droplet into contact with a surface of a salt solution by bringing the delivery pen tip toward the salt solution; and
compressing the droplet against the surface of the salt solution for a period of time until the spheroid is formed.
US Pat. No. 10,888,518

ORODISPERSIBLE TABLET CONTAINING ESTETROL

1. A process of making an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg and containing at least 100 ?g of an estetrol component, comprising:providing carrier particles having a volume median diameter of from 10 ?m to 400 ?m;
providing an aqueous liquid comprising water in an amount of at least 60 wt. %, the estetrol component in an amount of 1-40 wt. %, and, optionally, one or more other pharmaceutically acceptable ingredients in an amount of 0-40 wt. %;
mixing 1 part by weight of the aqueous liquid with 0.5-20 parts by weight of the carrier particles to produce wet particles;
removing water from the wet particles to produce loaded particles;
optionally, mixing the loaded particles with one or more tabletting excipients to produce a mixture; and
forming the loaded particles or the mixture into a solid dosage unit having a weight between 30 and 1,000 mg and containing at least 100 ?g of the estetrol component, wherein the estetrol component is selected from one or more of estetrol and estetrol esters.
US Pat. No. 10,889,800

METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNS)

New York Stem Cell Founda...

1. A method of generating basal forebrain cholinergic neurons (BFCNs) comprising:culturing pluripotent stem cells (PSCs) in a basal media comprising an inhibitor of transforming growth factor beta (TGF-?) signaling and an activator of sonic hedgehog (Shh) signaling thereby inducing neuroectodermal differentiation, wherein the inhibitor of TGF-? signaling is SB431542 and LDN193189 and the activator of Shh signaling is smoothened agonist (SAG) and purmorphamine, and
wherein the basal media lacks basic fibroblast growth factor (bFGF), TGF-?, lithium chloride (Li—Cl), GABA and pipecolic acid, thereby generating BFCNs.
US Pat. No. 10,889,545

CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT

Daewoong Pharmaceutical C...

1. A crystalline form I of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine fumarate having peaks at diffraction angles (2?±0.2°) of 7.9°, 11.9° and 24.0° in an X-ray powder diffraction pattern.
US Pat. No. 10,889,801

METHODS OF PRODUCING RPE CELLS

BioLamina AB, Sundyberg ...

1. A method of obtaining retinal pigment epithelium (RPE) cells, comprising:culturing one or more stem cells on a substrate comprising a laminin, wherein the laminin is an intact protein or a protein fragment, and wherein the laminin is laminin-521 or laminin-511;
exposing the stem cells to a first cell culture medium that contains a growth factor, wherein the growth factor is basic fibroblast growth factor (FGF2), the first cell culture medium being completely chemically defined and xeno-free, wherein the growth factor maintains the stem cells in a pluripotent state;
after a first time period, removing the first cell culture medium and exposing the stem cells to a second cell culture medium that does not contain the growth factor, the second cell culture medium being completely chemically defined and xeno-free, wherein removal of the growth factor causes differentiation of the stem cells to RPE cells.
US Pat. No. 10,890,569

COLORIMETRIC SENSOR ARRAYS BASED ON NANOPOROUS PIGMENTS

THE BOARD OF TRUSTEES OF ...

1. A method of making a colorimetric array comprising:depositing a first liquid at a first point on a substrate;
depositing a second liquid at a second point on the substrate;
converting the first liquid into a first spot on the substrate; and
converting the second liquid into a second spot on the substrate,
wherein the first spot comprises a first nanoporous pigment and a first immobilized, chemoresponsive colorant and the second spot includes the second nanoporous pigment and a second immobilized, chemoresponsive colorant,
wherein the first and second liquids further comprise at least one ingredient selected from the group consisting of a nanoporous material precursor for the first nanoporous pigment, a nanoporous material precursor for the second nanoporous pigment, a solvent, an oxidant, a reductant, a catalyst, additive and a surfactant, or a combination thereof,
wherein the first and second liquids are each formed according to the following process:
combining a precursor for an organically modified silica, a solvent, a nanoporous material precursor for the first or second nanoporous pigment and the first or second chemoresponsive colorant to form a mixture; and
hydrolyzing the mixture to form a sol.
US Pat. No. 10,892,107

METHOD FOR PRODUCING TITANIUM OXIDE PARTICLES, TITANIUM OXIDE PARTICLES, DISPERSION SOLUTION OF TITANIUM OXIDE PARTICLES, TITANIUM OXIDE PASTE, TITANIUM OXIDE FILM, AND DYE-SENSITIZED SOLAR CELL

SUMITOMO OSAKA CEMENT CO....

1. A method for producing titanium oxide particles, comprising:producing a mixed solution by mixing a hydrolysis product of a titanium alkoxide or a titanium metal salt with a compound having a five-membered ring containing nitrogen; and
generating titanium oxide fine particles by heating at a temperature of 150° C. to 350° C. and pressurizing the mixed solution,
wherein a ratio (DXRD(100)/DXRD(100)) of a Scherrer diameter (DXRD(100)) that is computed from a half-value width of a diffraction peak of a (100) plane to a Scherrer diameter (DXRD(100)) that is computed from a half-value width of a diffraction peak of a (001) plane in an X-ray diffraction pattern of the titanium oxide particles is 0.2 to 1.0, and
the compound having the five-membered ring containing nitrogen is at least one compound selected from the group consisting of pyrrole, indole, pyrrolidine, isothiazole, isoxazole, furazan, carbazole, and 1,5-diazabicyclo-[4.3.0]-5-nonene.
US Pat. No. 10,888,520

COATED PARTICLE AND METHOD FOR PRODUCING COATED PARTICLE

KOBE GAKUIN EDUCATIONAL F...

1. A coating particle comprising a nuclear particle covered with a coating layer, wherein the coating layer is a layer comprising hydroxyalkyl cellulose particles and a binder; and the nuclear particle has a volume average particle size of from 50 to 500 ?m and the hydroxyalkyl cellulose particle has a volume average particle size of from 0.1 to 20 ?m.
US Pat. No. 10,889,802

B-CELL CULTIVATION METHOD

HOFFMANN-LA ROCHE INC., ...

1. A method for co-cultivating one or more B-cells comprising the steps ofcultivating EL4-B5 cells to a cell density of more than 1,000,000 cells/ml to 1,500,000 cells/ml, and
incubating the one or more B-cells with an aliquot of the EL4-B5 cells obtained in the previous step.
US Pat. No. 10,889,803

TRANSGENIC MACROPHAGES, CHIMERIC ANTIGEN RECEPTORS, AND ASSOCIATED METHODS

Thunder Biotech, Inc, Al...

1. A method of administering a monocyte or macrophage cell to a subject, the method comprising:administering to the subject a monocyte or macrophage cell comprising a plasmid encoding a chimeric receptor;
wherein the chimeric receptor comprises:
a cytoplasmic domain;
a transmembrane domain; and
an extracellular ligand binding domain;
wherein the binding of a ligand to the extracellular ligand binding domain activates the cytoplasmic portion; and
wherein activation of the cytoplasmic portion provides a signal for polarization to an M2 macrophage.
US Pat. No. 10,888,522

CONTROLLED-RELEASE COMPOSITIONS OF MELATONIN COMBINED WITH SEDATIVE AND/OR ANALGESIC INGREDIENTS

1. A composition comprising an oral pharmaceutical dosage form comprising:a solid core including a combination of melatonin and a GABA receptor agonist ingredient located together within a first acidified polymeric matrix;
an expedited release portion including a first portion of the GABA receptor agonist ingredient in the solid core, the expedited release portion being effective to release substantially all of the GABA receptor agonist ingredient therein within about 2 hours from placement in a 0.1 N HCl solution; and
a sustained release portion including a second portion of the GABA receptor agonist ingredient in the solid core, the sustained release portion being effective to release substantially all of the GABA receptor agonist ingredient therein from at least 5 to about 8 hours from placement in a phosphate buffer with a pH of 6.8.
US Pat. No. 10,889,804

PANCREATIC STROMAL PROGENITOR CELLS

ALFRED E. MANN INSTITUTE ...

1. A composition comprising:human pancreatic stromal progenitor (PSP) cell suspension comprising from about 1×101 PSP cells/mL to about 1×1010 PSP cells/mL, and a carrier, wherein the amount of PSP cells in the composition is effective for treatment of a human that has a disease that affects how the human body uses blood sugar;
wherein,
the human PSP cells consist of a subpopulation of PSP cells that are separated from an initial population of human PSP cells isolated from a pancreatic tissue of a human;
wherein the human PSP cells in the human PSP cell suspension consist of only the top 30% of PSP cells from the initial population of the human PSP cells isolated from the pancreatic tissue of the human that express IL6 at the highest level relative to the initial population of the human PSP cells isolated from the pancreatic tissue of the human; and
the PSP cells are positive for Sca1, CD1 OS, Vimentin, CD44, and CD29.
US Pat. No. 10,888,523

SOLID PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION

MILLENNIUM PHARMACEUTICAL...

1. A method of preparing a pharmaceutical composition comprising the steps of:(a-1) wet granulating at least one active ingredient that is the compound sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, or a crystalline form thereof, and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, and disintegrants in the presence of a suitable solvent to form a wet mixture;
(a-2) drying the wet mixture from step (a-1), to form dried granules;
(a-3) milling the dried granules from step (a-2), to form milled granules; and
(a-4) blending the milled granules from step (a-3) with a buffer that is sodium bicarbonate and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants, binders, disintegrants, lubricants and glidants;
wherein a filler is added during step (a-1), during step (a-4), or during both steps (a-1) and (a-4).
US Pat. No. 10,888,524

IMMEDIATE RELEASE TABLET OF DOFETILIDE

ENALTEC PHARMA RESEARCH P...

1. An immediate release tablet formulation comprising:a) dofetilide or a pharmaceutically acceptable salt thereof in an amount in the range of 0.05 to about 10% w/w;
b) a pharmaceutically acceptable diluent comprising microcrystalline cellulose in an amount ranging from about 5% to about 98% w/w;
c) a pharmaceutically acceptable disintegrant comprising croscarmellose sodium in an amount ranging from about 1% to about 20% w/w;
d) a glidant comprising colloidal silicon dioxide in an amount ranging from about 0.07% to about 3%; and/or a lubricant comprising magnesium stearate in an amount ranging from about 0.1% to about 3%; and
e) optionally a coating comprising a functional or non-functional coating, wherein the formulation releases at least 80 wt. % of the dofetilide or pharmaceutically acceptable salt thereof from the tablet within 15 minutes.
US Pat. No. 10,889,806

ENGINEERED PANTOTHENATE KINASE VARIANT ENZYMES

Codexis, Inc., Redwood C...

1. An engineered pantothenate kinase polypeptide comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 2, or to a functional fragment thereof, wherein said polypeptide or fragment thereof comprises an amino acid substitution corresponding to amino acid position 277 and/or 281 in SEQ ID NO: 2, wherein said polypeptide has increased ability to convert ethynyl glyceraldehyde to ethynyl glyceraldehyde phosphate when compared the wild-type polypeptide having the amino acid sequence SEQ ID NO: 2.
US Pat. No. 10,890,574

DIGESTION OF LEAD(0) AND SUBSEQUENT COLORIMETRIC DETECTION OF LEAD(II)

HACH COMPANY, Loveland, ...

1. A method for measuring a concentration of lead(0) in an aqueous sample, comprising:introducing an aqueous sample to a reaction vessel;
adding a copper(II) acetate material to the aqueous sample in the reaction vessel, wherein lead(0) within the aqueous sample reacts with the copper(II) acetate material to generate lead(II);
chelating unreacted copper(II) acetate material by introduction of an organosulfur compound to the aqueous sample in the reaction vessel;
adding a colorimetric indicator to the aqueous sample in the reaction vessel;
measuring a concentration of lead(II) in the aqueous sample by measuring a colorimetric change of the aqueous sample caused by a reaction of lead(II) within the aqueous sample with the colorimetric indicator; and
correlating the measurement of the concentration of lead(II) in the aqueous sample to the concentration of lead(0) in the aqueous sample.
US Pat. No. 10,888,525

HYPROMELLOSE ACETATE SUCCINATE AND METHOD FOR PRODUCING THE SAME

SHIN-ETSU CHEMICAL CO., L...

1. A method for producing hypromellose acetate succinate, the method comprising:an esterification step of adding acetic anhydride and succinic anhydride to a solution of hypromellose in glacial acetic acid in the presence of sodium acetate to obtain a reaction product mixture, wherein the succinic anhydride is added intermittently; and
a precipitation step of mixing the reaction product mixture with water to precipitate the hypromellose acetate succinate,
wherein an amount of the acetic anhydride is 0.4 to 1.3 mol relative to 1 mol of the hypromellose, and wherein a solution of 10 parts by weight of the obtained hypromellose acetate succinate in 100 parts by weight of a mixed solvent having a weight ratio of methylene chloride to methanol of 1:1 has a viscosity at 20° C. of 135 mPa.s or less.
US Pat. No. 10,889,807

LIPOLYTIC ENZYME VARIANTS

DSM IP ASSETS B.V., Heer...

1. A variant polypeptide having lipolytic activity, wherein the variant has an amino acid sequence which, when aligned with the amino acid sequence as set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue at a position corresponding to any of the positions 113, 122, 138, 141, 179, 282, 284, 286, 295, said positions being defined with reference to SEQ ID NO: 2,and wherein said variant has at least 85% identity with the mature polypeptide as set out in SEQ ID NO: 2.
US Pat. No. 10,888,526

CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY

GLORIANA THERAPEUTICS SAR...

1. A capsule for delivery of a secreted biologically active compound to a subject, the capsule comprising:a. a biocompatible outer membrane and an inner core,
b. said inner core comprising monoclonal cells,
c. said monoclonal cells comprising a heterologous expression construct comprising a structural gene either
i. coding for a secreted biologically active peptide or,
ii. coding for a polypeptide or a siRNA contributing to the generation in the cells of a biologically active secreted compound,
d. said gene being located between two inverted repeats which are substrates for a transposase or other integrases,
wherein said monoclonal cells maintain a high and stable expression level of the polypeptide or siRNA of i or ii absent the presence of a selective pressure compared to the same cells generated without a transposase;
wherein the thickness of the outer membrane is between 2 and 200 microns;
wherein said capsule has a volume between 1 ?L and 5 ?L; and
further wherein said capsule contains less than 103 monoclonal cells.
US Pat. No. 10,889,808

CRISPR-ASSOCIATED (CAS) PROTEIN

Locanabio, Inc., San Die...

1. An expression cassette comprising:a polynucleotide encoding:
a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein, wherein the Cas protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:44, an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:37, an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:39, and an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:44; the polynucleotide is operably linked to a regulatory sequence; and
one or more cognate nucleic acid guides, wherein the one or more cognate nucleic acid guides comprise a repeat sequence and a spacer sequence, wherein the repeat sequence and the spacer sequence do not naturally occur together, wherein the Cas protein is capable of forming one or more nucleoprotein complexes with the one or more cognate nucleic acid guides, and wherein each nucleoprotein complex is capable of site-directed binding to a target nucleic acid sequence.
US Pat. No. 10,888,527

STABLE SOLID PHARMACEUTICAL FORMULATIONS CONTAINING 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYLCOHEXANEDIONE

DIPHARMA S.A., Chiasso (...

1. A stable solid pharmaceutical formulation comprising 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione as a pharmaceutically active ingredient, pregelatinized starch and stearic acid.
US Pat. No. 10,889,809

METHODS OF RECOMBINANTLY PRODUCING NEUTRAL PROTEASE ORIGINATING FROM PAENIBACILLUS POLYMYXA

Roche Diagnostics Operati...

1. A method of isolating living cells in vitro, the method comprising:(a) incubating a tissue source in vitro with a recombinant neutral protease consisting of the amino acid sequence from position 289 to position 592 of SEQ ID NO:5 for a time sufficient to proteolytically degrade extracellular matrix protein components of the tissue source; and
(b) isolating living cells from the proteolytically degraded tissue source.
US Pat. No. 10,888,528

IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS

Clexio Biosciences Ltd., ...

1. An immediate release abuse deterrent oral dosage form comprising:core-shell particles that include
an active pharmaceutical ingredient that is ketamine, esketamine, or a pharmaceutically acceptable salt thereof;
a core comprising a gelling polymer and up to 10% by weight of the total amount of the active pharmaceutical ingredient in said core-shell particles;
an active pharmaceutical layer surrounding the core and comprising the active pharmaceutical ingredient; and,
at least one layer surrounding said active pharmaceutical layer, wherein the at least one layer comprises a pH-sensitive film comprising a pH-sensitive polymer that is insoluble in water at a pH greater than 5;
wherein the dosage form demonstrates an immediate release profile of the active pharmaceutical ingredient when administered to a human in therapeutic doses, and an extended release profile of the active pharmaceutical ingredient when administered to a human in supratherapeutic doses, and,
wherein the dosage form resists attempted abuse of the active pharmaceutical ingredient by injection or nasal insufflation.
US Pat. No. 10,888,529

VEHICLES FOR THE TRANSFECTION OF MIRNAS

UNIVERSIDAD DEL PAIS VASC...

1. A nanoparticle comprising (i) between 60% and 99% by weight, based on the total weight of the nanoparticle, of a sorbitan ester; (ii) a positively charged substance, (iii) miR-20a, and (iv) a negatively charged substance.
US Pat. No. 10,889,042

PROCESS FOR THE PRODUCTION OF STRETCH FILM

SABIC GLOBAL TECHNOLOGIES...

17. A process for the production of a stretch film comprising:a) providing a film web comprising a center portion comprising linear low density polyethylene (LLDPE) and edge portions comprising low density polyethylene (LDPE) using an encapsulation die, wherein the film web is not produced on a substrate,
wherein the LLDPE is a homopolymer and wherein the amount of the LLDPE in the center portion of the film web is at least 90 wt %,
wherein the LDPE in the edge portions of the film web is a copolymer of ethylene and a di- or higher functional (meth) acrylate, and wherein the amount of the LDPE in the edge portions of the film web is at least 90 wt %,
b) solidifying the film web to obtain a solidified film web comprising a solidified center portion comprising LLDPE and solidified edge portions comprising LDPE,
c) removing the solidified edge portions from the solidified film web to obtain the stretch film, and
d) recycling the removed edge portions that are free of any substrate to a feed for forming the center portion of the film web.
US Pat. No. 10,888,530

IMPLANTABLE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF

AcuityBio Corporation, N...

1. An implantable composition comprising an acellular collagen matrix together with poly(lactic-co-glycolic acid) copolymer (PLGA), polyethylene glycol (PEG) 8000 and paclitaxel, wherein:the PLGA has a molecular weight ranging from about 20,000 g/mol to about 250,000 g/mol;
the PLGA has a lactide/glycolide molar ratio of about 40:60 to about 60:40;
the paclitaxel is present in an amount of 50% by weight or less based on the total weight of the PLGA and PEG 8000; and
the PEG 8000 is present in an amount of between about 5% by weight to about 35% by weight based on the total weight of the PLGA and the paclitaxel.
US Pat. No. 10,889,812

SHORT NON-CODING PROTEIN REGULATORY RNAS (SPRRNAS) AND METHODS OF USE

UNIVERSITY OF MARYLAND, B...

1. An isolated nucleic acid molecule comprising:(i) a short non-coding protein regulatory RNA (sprRNA) that is at least 90% identical to any one of SEQ ID NOS:193-196, 198-267, 269-413, 415-445, 447-462, 464-469, 471-474, 476-486, or 560-2802; and
(ii) at least one adaptor sequence, wherein the adaptor sequence has been added to one or both of a 3? end and a 5? end of the sprRNA.
US Pat. No. 10,890,580

REVERSIBLE CELL LABELLING WITH CONJUGATES HAVING TWO RELEASABLE BINDING SITES

Miltenyi Biotec, GmbH, B...

1. A method for detecting a target moiety in a sample of biological specimens by:a) providing at least one conjugate with the general formula (I)
An-P-Bm-Cq-Xo  (I)
wherein
A: is an antigen recognizing moiety A;
P: is an enzymatically degradable spacer;
B: is a first binding moiety;
C is a second binding moiety;
X: is a detection moiety;
n is an integer greater than 1 and less than 100;
m, q, o are integers between 1 and 100, and
wherein B and C are non-covalently bound to each other and A and B are covalently bound to P, and wherein the antigen recognizing moiety A is a Fab fragment of an antibody against an antigen and wherein the enzymatically degradable spacer is a polysaccharide;
b) labelling the target moiety recognized by the antigen recognizing moiety A with the at least one conjugate with the general formula (I);
c) detecting the labelled target moiety via detecting moiety Xo;
d) cleaving Cq-Xo by disrupting the non-covalent bond between Bm and Cq from the labelled target moiety; and
e) cleaving the binding moiety Bm from the labelled target moiety by enzymatically degrading spacer P thereby removing A, B, C, P, X form the target moiety.
US Pat. No. 10,889,813

PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

ALNYLAM PHARMACEUTICALS, ...

1. A double stranded ribonucleic acid (dsRNAi) agent for inhibiting expression of programmed cell death 1 ligand 1 (PD-L1), wherein said dsRNAi agent comprises a sense strand and an antisense strand, wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of nucleotides 3222-3243 of the nucleotide sequence of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the complementary portion of the nucleotide sequence of SEQ ID NO:2,wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand comprise nucleotide modifications, and
wherein said sense strand is conjugated to an N-acetylgalactosamine (GalNAc) derivative attached at the 3?-terminus.
US Pat. No. 10,888,532

BUTORPHANOL-CONTAINING PATCH

HISAMITSU PHARMACEUTICAL ...

1. A patch comprising:a backing layer; and
an adhesive layer, wherein
the adhesive layer contains at least one drug selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof and a silicone-based adhesive base,
a content of the silicone-based adhesive base in the adhesive layer is 50 to 97% by mass relative to the total mass of the adhesive layer, and
a mass per unit area of the adhesive layer is 40 to 80 g/m2.
US Pat. No. 10,889,814

MONOCARBOXYLATE TRANSPORTER 4 (MCT4) ANTISENSE OLIGONUCLEOTIDE (ASO) INHIBITORS FOR USE AS THERAPEUTICS IN THE TREATMENT OF CANCER

The University of British...

and wherein the ASO comprises a modified internucleoside linkage, a modified sugar moiety, or modified nucleobase, and wherein the ASO is not longer than 21 nucleotides in length.
US Pat. No. 10,888,533

TRANSDERMAL COMPOSITION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT

ICURE PHARMACEUTICAL INC....

1. A transdermal composition containing donepezil as an active ingredient, the transdermal composition comprising:(a) a backing layer;
(b) a drug-containing matrix layer comprising, based on a total weight of the drug-containing matrix layer,
(b-1) 15-55 wt % of donepezil or a pharmaceutically acceptable salt thereof,
(b-2) 25-70 wt % of an EVA-based adhesive,
(b-3) 5-20 wt % of at least one selected from the group consisting of a pyrrolidone derivative and a C8-18 aliphatic derivative, and
(b-4) 1-10 wt % of triacetin or a citric acid derivative,
(c) a polymer adhesive matrix layer comprising, based on a total weight of the polymer adhesive matrix layer, 60 wt % or more of an acrylic adhesive, wherein the acrylic adhesive does not contain a functional group; and
(d) a release layer;
wherein the EVA-based adhesive is an ethylene vinyl acetate (EVA) copolymer; and
wherein the polymer adhesive matrix layer excludes donepezil or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,889,559

METHOD FOR THE PREPARATION OF A MONOTHIOCARBONATE COMPOUND

BASF SE, Ludwigshafen am...

1. A process for preparing a compound having at least one monothiocarbonate group, the process comprising:reacting
a compound having at least one mercaptoalcohol group, and
a dialkylcarbonate,
in the presence of a catalyst,
wherein the catalyst is a salt of a metal selected from group IIIb or IVb of the periodic table of elements.
US Pat. No. 10,889,815

RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA)

SIRNA THERAPEUTICS, INC.,...

1. A compound comprising:(I) a short interfering nucleic acid (siNA) molecule capable of inhibiting expression of a human huntingtin gene, wherein the human huntingtin gene comprises a nucleotide sequence of GenBank Accession Number NM_002111, said siNA molecule consisting of a single-stranded polynucleotide comprising a nucleotide sequence complementary to a huntingtin RNA, wherein said single-stranded polynucleotide:
i) is about 19 to 20 nucleotides in length;
ii) comprises 10 or more phosphorothioate internucleotide linkages;
iii) comprises 10 or more modified pyrimidines chosen from 2? deoxy pyrimidine, 2?-O-methyl pyrimidine, 2?-deoxy-2?-fluoro pyrimidine, locked nucleic acid (LNA) pyrimidine, 2?-methoxyethoxy (MOE) pyrimidine, or a combination thereof; and
(II) a galactosamine.
US Pat. No. 10,889,816

VON WILLEBRAND FACTOR (VWF)—TARGETING AGENTS AND METHODS OF USING THE SAME

DUKE UNIVERSITY, Durham,...

1. An aptamer comprisinga polynucleotide comprising from 5? to 3? (a) a polynucleotide having at least 70% sequence identity to SEQ ID NO: 1 comprising a first stem forming region comprising 3 nucleotides, a first loop region comprising the nucleotide sequence AAC, a second stem forming region comprising 3 nucleotides, a second loop region comprising the nucleotide sequence CC and a third stem forming region consisting of 2-8 nucleotides, (b) a third loop region consisting of 1-12 nucleotides or a spacer sequence, and (c) a polynucleotide having at least 70% sequence identity to SEQ ID NO:2 comprising a fourth stem forming region consisting of 2-8 nucleotides and forming a stem with the third stem forming region, a fourth loop region comprising the nucleotide C, a fifth stem forming region comprising 3 nucleotides and forming a stem with the second stem forming region, a fifth loop region comprising the nucleotide sequence CAGA, and a sixth stem forming region comprising 3 nucleotides and forming a stem with the first stem forming region,
wherein the polynucleotide comprises an unmodified form or comprises a modified form comprising at least one nucleotide base modification, and
wherein the aptamer is no more than 53 nucleotides in length.
US Pat. No. 10,888,535

SKIN DISINFECTANT COMPOSITION

OTSUKA PHARMACEUTICAL FAC...

1. A composition for skin disinfection comprising olanexidine gluconate, a coloring agent, alkyl dimethylamine oxide, and 0 (W/V) % to 4 (W/V) % of polyoxyethylene alkyl ether, wherein the ratio of the concentration of alkyl dimethylamine oxide to the total concentration of alkyl dimethylamine oxide and polyoxyethylene alkyl ether is 0.18 or more.
US Pat. No. 10,889,561

PROCESS OF MAKING SOMATOSTATIN MODULATORS

CRINETICS PHARMACEUTICALS...

1. A method of treating acromegaly or a neuroendocrine tumor, or combination thereof, in a human comprising orally administering to the human with acromegaly or a neuroendocrine tumor, or combination thereof, a pharmaceutical composition comprising the compound 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile monohydrochloride, or solvate thereof; and at least one pharmaceutically acceptable excipient, wherein 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile monohydrochloride, or solvate thereof is crystalline and is characterized as having: an X-ray powder diffraction (XRPD) pattern with peaks at 4.5° 2-Theta, 9.1° 2-Theta, 10.2° 2-Theta, 16.3° 2-Theta, 18.4° 2-Theta, and 19.1° 2-Theta; an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 1; a Differential Scanning calorimetry (DSC) thermogram with an endotherm having an onset at about 207° C. and a peak at about 220° C.; a Differential Scanning calorimetry (DSC) thermogram substantially the same as shown in FIG. 2(a); an infrared (IR) spectrum with peaks at 2223 cm?1, 1620 cm?1, 1595 cm?1, 1457 cm?1, 1238 cm?1, 1220 cm?1, and 1117 cm?1; an infrared (IR) spectrum substantially the same as shown in FIG. 3; an unchanged XRPD when heated up to about 200° C., upon exposure to more than 90% relative humidity for about 24 hours, or upon exposure to about 75% RH and 40° C. over one week, or combinations thereof; or combinations thereof.
US Pat. No. 10,889,817

OLIGONUCLEOTIDE THERAPY FOR LEBER CONGENITAL AMAUROSIS

ProQR Therapeutics II B.V...

1. An oligonucleotide consisting of the nucleotide sequence of SEQ NO: 5, 6, or 7, wherein the oligonucleotide comprises a modified ribose that is substituted at the 2? position with a substituent selected from the group consisting of:(i) OH;
(ii) F;
(iii) substituted or unsubstituted, linear or branched lower (C1-C10) alkyl, alkenyl, alkynl, alkaryl, allyl, or aralkyl, that may be interrupted by one or more heteroatoms,
(iv) O-, S-, or N-alkyl,
(v) O-, S-, or N-alkenyl,
(vi) O-, S-, or N-alkynyl,
(vii) O-, S-, or N-allyl,
(viii) O-alkyl-O-alkyl, -methoxy, or aminopropoxy,
(ix) methoxyethoxy,
(x) dimethylaminooxyethoxy, and
(xi) dimethylaminoethoxyethoxy.
US Pat. No. 10,888,536

METHOD OF IMPROVEMENT OF INSULIN SENSITIVITY IN OBESE PATIENTS

FOOYIN UNIVERSITY, Kaohs...

1. A method of improvement of insulin sensitivity in obese patients, comprising:administering propanamide to a subject in need thereof to increase activity of ATP synthesis, decreasing inflammation, reducing accumulation of visceral fat and ameliorating obesity-induced hyperglycemia and hyperinsulinemia.
US Pat. No. 10,889,818

TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMA

CELL SIGNALING TECHNOLOGY...

1. A composition, comprisinga biological sample of from a human having cancer, and
a nucleic acid reagent comprising a primer pair,
wherein the primer pair hybridizes to a polynucleotide encoding a Sodium-Dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2)-Proto-Oncogene Tyrosine Protein Kinase ROS precursor (ROS) fusion polypeptide, and
wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 4.
US Pat. No. 10,888,537

PHARMACEUTICAL COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS

Amarin Pharmaceuticals Ir...

1. A pharmaceutical composition comprising (a) docosapentaenoic acid in an amount of about 5% by weight of all fatty acids; (b) eicosapentaenoic acid in an amount of 60% to 95% by weight, of all fatty acids present in the composition; and (c) at least one surfactant.
US Pat. No. 10,889,819

VISCERAL ADIPOSE TISSUE MACROPHAGE-TARGETED GENE/CARRIER COMPLEX FOR PREVENTING OR TREATING OBESITY-INDUCED TYPE II DIABETES

INDUSTRY-UNIVERSITY COOPE...

1. A composition for preventing or treating obesity-induced type II diabetes, comprising:a gene/carrier complex that contains
(i) at least one shRNA which inhibits expression of tumor necrosis factor-? converting enzyme (TACE) and is selected from the group consisting of SEQ ID NOS: 1 to 5; and
(ii) a gene carrier which contains the sequences of SEQ ID NO: 6 targeting visceral adipose tissue macrophages and a 9R (SEQ ID NO: 14) peptide.
US Pat. No. 10,890,587

METHOD AND COMPOSITIONS FOR DETECTING AN ADENOMA-ADENOCARCINOMA TRANSITION IN CANCER

Quest Diagnostics Investm...

1. A method for isolating a cancer stem cell (CSC) in a colonic tumor, comprisinga. contacting one or more tissue sections of a colonic tumor sample with an antibody that specifically binds to PTEN and an antibody that specifically binds to SMAD4,
b. detecting the presence or absence of an alternating spatial pattern of PTEN expression and an alternating spatial pattern of SMAD4 expression, and
c. identifying the presence of CSCs in the colonic tumor where the alternating spatial pattern of PTEN expression and the alternating spatial pattern of SMAD4 expression are detected or identifying the absence of CSCs in the colonic tumor when the alternating spatial pattern of PTEN expression and the alternating spatial pattern of SMAD4 expression are not detected; and
d. isolating one or more identified CSCs from the tissue section.
US Pat. No. 10,888,538

PUFA SALT FORMULATIONS (I)

DSM IP ASSETS B.V., Heer...

1. A particulate solid formulation comprising:(i) at least one polyunsaturated fatty acid (PUFA) salt, and
(ii) 10-75 wt. % of a casein phosphopeptide.
US Pat. No. 10,889,820

FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE WOUND HEALING

ALBERT EINSTEIN COLLEGE O...


US Pat. No. 10,888,539

METHODS OF TREATING OR PREVENTING PROSTATE CANCER

Amarin Pharmaceuticals Ir...

1. A method of treating prostate cancer in a subject having an elevated PSA level of at least about 2.5 ng/mL and a baseline triglyceride level of 200 mg/dL to 499 mg/dL, the method comprising:(a) determining the elevated PSA level and the baseline triglyceride level in the subject, and based on the determined elevated PSA level and the determined baseline triglyceride level;
(b) administering a pharmaceutical composition comprising 4 g per day of ethyl eicosapentaenoate to the subject for a period of time effective to reduce the subject's PSA level by at least 50%, wherein the pharmaceutical composition comprises at least 96%, by weight of all fatty acids (and/or derivatives thereof) present, ethyl eicosapentaenoate and substantially no or no amount of docosahexaenoic acid or derivative thereof; and
(c) determining a lower PSA level in the subject after administering the pharmaceutical composition that is at least 50% lower than the determined elevated PSA level.
US Pat. No. 10,889,821

ORGANIC ACID SYNTHESIS FROM C1 SUBSTRATES

Alliance for Sustainable ...

1. An engineered cell, comprising an exogenously added gene encoding a 3-dehydroshikimate dehydratase (AroZ), a protocatechuic acid decarboxylase (AroY), a catechol 1,2-dioxygenase (CatA), a phospho-2-dehydro-3-deoxyheptonate aldolase (AroG), an anthranilate synthase (TrpE), a phosphoenolpyruvate synthase, or a transketolase; wherein the engineered cell is a methanotroph and is able to convert a C1 substrate to a muconic acid and the cell comprises genes encoding the 3-dehydroshikimate dehydratase (AroZ), the protocatechuic acid decarboxylase (AroY), and the catechol 1,2-dioxygenase (CatA).
US Pat. No. 10,890,589

METABOLIC BIOMARKERS FOR MEMORY LOSS

Georgetown University, W...

1. A method of treating memory impairment in a subject, the method comprisinga) analyzing at least one plasma sample from the subject in a fasting state to determine the concentrations of each component of a set of metabolites, wherein the components comprise C3, phosphocholine (PC) aa C32:0, PC aa C40:5, C5-OH (C3-DC-M), PC ae C34:0, C18:1-OH, PC aa C34:4, PC aa C38:4, C5, PC aa C38:3, lysoPC a C18:0, C10:2, C12:1, C16:2, C10:1, asparagine (Asn) and asymmetric dimethylarginine (ADMA), and
b) administering a treatment for memory impairment to the subject when:
(i) the concentrations of the components C3, PC aa C32:0, PC aa C40:5, C5-OH (C3-DC-M), PC ae C34:0, C18:1-OH, PC aa C34:4, PC aa C38:4, C5, PC aa C38:3, lysoPC a C18:0, C10:2, Asn, and ADMA in the subject's set of metabolites are lower as compared to their concentrations in a set of metabolites from subjects determined to define normal concentrations, and
(ii) the concentrations of the components C12:1, C16:2, and C10:1 in the subject's set of metabolites are higher as compared to their concentrations in the set of metabolites from subjects determined to define normal concentrations.
US Pat. No. 10,888,540

ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE

The William M. Yarbrough ...

1. A surfactant formulation, comprising:a lysine derivative, wherein the lysine derivative comprises an ?-nitrogen and a ?-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least 8 carbon atoms is bound to the ?-nitrogen, and further wherein the ?-nitrogen forms part of an isothiocyanate functional group; and
a solvent.
US Pat. No. 10,889,822

CONSTRUCT AND SEQUENCE FOR ENHANCED GENE EXPRESSION

Proteonic Biotechnology I...

1. A nucleic acid construct comprising a first promoter, a second promoter, and a single nucleotide sequence of interest, wherein said first promoter and second promoter are constitutive promoters and are both operably linked to said single nucleotide sequence of interest, and wherein said second promoter is an intronic promoter flanked by a first intronic sequence located upstream of said second promoter and a second intronic sequence located downstream of said second promoter, and wherein said single nucleotide sequence of interest is under the control of said first promoter and said second promoter, and wherein said first promoter and said first intronic sequence comprise the sequence of SEQ ID NO: 1 and said second intronic sequence comprises the sequence of SEQ ID NO: 19.
US Pat. No. 10,890,590

DIAGNOSTIC DEVICES AND METHODS

Ellume Limited, Queensla...

1. A pregnancy test device for identifying pregnancy in a human or animal body based on a biological sample obtained from the human or animal body, the test device comprising:a lateral flow test strip comprising one or more test portions configured to bind:
human chorionic gonadotropin (hCG), when present, in the biological sample; and
luteinizing hormone (LH), when present, in the biological sample; and
a reader that analyses the one or more test portions and determines a level of hCG in the biological sample based on an amount of hCG bound at the one or more test portions and determines a level of LH in the biological sample based on an amount of LH bound at the one or more test portions, wherein the reader comprises a processor and a non-transitory computer-readable memory medium, the non-transitory computer-readable memory medium comprising instructions that cause the processor to:
determine which of a plurality of discrete LH ranges the determined level of LH falls within, wherein the processor associates a different hCG threshold level with each one of the LH ranges,
wherein the plurality of discrete LH ranges comprises a first LH range below a first LH threshold level and a second LH range above the first LH threshold level, the first LH threshold level being between 10 and 30 IU/L,
wherein a first hCG threshold level of between 1.0 and 3.0 IU/L is associated with the first LH range; and a second hCG threshold level that is at least 2.0 IU/L greater than the first hCG threshold is associated with the second LH range;
select the hCG threshold level that is associated with the LH range which the determined level of LH falls within; and
identify pregnancy in the body if the determined level of hCG is above the selected hCG threshold level.
US Pat. No. 10,890,846

PHOTOSENSITIVE RESIN COMPOSITION AND CURED FILM PREPARED THEREFROM

Rohm and Haas Electronic ...

7. A silicon-containing cured film formed by a method of forming a pattern, comprising:forming a silicon-containing film on a surface of a substrate using a photosensitive resin composition, comprising (A) a siloxane polymer containing a fluorine atom, (B) a 1,2-quinonediazide compound and (C) an epoxy compound;
patterning the silicon-containing film using light; and
dry etching the patterned silicon-containing film and the substrate to form a pattern in the substrate,
wherein the siloxane polymer containing a fluorine atom(A) comprises at least one structural unit derived from a silane compound represented by the following formula 1:
(R1)nSi(OR2)4-n  [Formula 1]
in formula 1, R1 is a fluorine atom or a monovalent hydrocarbon containing a fluorine atom, wherein, in case where R1 is the monovalent hydrocarbon, hydrogen atoms may be partially or wholly substituted, and in case where a plurality of R1 is present in the same molecule, each R1 may be identical to or different from one another;
R2 is hydrogen, alkyl having 1 to 6 carbon atoms, acyl having 2 to 6 carbon atoms, or aryl having 6 to 15 carbon atoms, wherein, in case where a plurality of R2 is present in the same molecule, each R2 may be identical to or different from one another, and in case where R2 is alkyl, acyl or aryl, hydrogen atoms may be partially or wholly substituted; and
n is an integer from 1 to 3,
wherein the siloxane polymer (A) containing a fluorine atom is included in an amount of 50 to 95 wt % based on the total weight of the solid content of the composition excluding solvents, and
wherein the epoxy compound (C) is included in the photosensitive resin composition in an amount of 5 to 25 parts by weight based on 100 parts by weight of the siloxane polymer (A) on the basis of the solid content excluding solvents.
US Pat. No. 10,888,541

METHOD AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF BROAD SPECTRUM VIRUS AILMENTS COMPRISING A CALCIUM CHANNEL BLOCKER OR A CALMODULIN BLOCKER

DR. KENNETH ADAMS MEDICIN...

1. A method for treating cold sores in a human comprising: topically administering to the said human a therapeutically effective amount of a composition comprising a calcium channel blocker as the active agent, and a pharmaceutically acceptable diluent or carrier, and wherein said calcium channel blocker is verapamil or diltiazem and wherein the composition is a cream.
US Pat. No. 10,889,823

BACTERIA-BASED PROTEIN DELIVERY

Universitaet Basel, Base...

1. A recombinant Gram-negative bacterial strain transformed with a vector which comprises in the 5? to 3? direction:a promoter;
a first nucleic acid comprising a first DNA sequence encoding a delivery signal from a bacterial T3SS effector protein, operably linked to said promoter; and
a second nucleic acid comprising a second DNA sequence encoding a heterologous protein, which is a protein or part thereof which does not belong to the entire natural protein complement of the recombinant Gram-negative bacterial strain, wherein the second DNA sequence is fused in frame to the 3? end of said first DNA sequence,
wherein the heterologous protein is a protein or a part thereof involved in apoptosis or apoptosis regulation, and
wherein the recombinant Gram-negative bacterial strain is a Yersinia strain and the delivery signal comprises the YopE effector protein or an N-terminal part thereof, or
wherein the recombinant Gram-negative bacterial strain is a Salmonella strain and the delivery signal comprises the SopE or the SteA effector protein or an N-terminal part thereof,
and
wherein the heterologous protein or part thereof involved in apoptosis or apoptosis regulation is selected from the group consisting of FADD, Bad, Bid, t-Bid, Caspase 3, Caspase 3 p17, Caspase 3 p10/12, Bid BH3, Bax BH3, Noxa, Bim, Bax, Bak, Nbk/Bik, ASC, TRAF2, TRADD, Apaf1, Caspase 10, Caspase 8, Caspase 1, Bcl-2, Puma, RIP, z-Bid, z-t-Bid, z-BIM, Ink4A, Ink4B, Ink4C, TEVsite-Flag-Ink4C, TEVsite-Ink4C, Ubiquitin-Flag-Ink4C-MycHis, and Pleckstrin homology domain from human Akt.
US Pat. No. 10,890,591

METHODS AND DOSE PACKS FOR MONITORING MEDICATION ADHERENCE

Synapse Biosciences, LLC,...

1. A method for monitoring adherence of a subject to a dosing schedule, the method comprising:providing a dose pack for the subject, the dose pack comprising a pair of a biomarkingly effective dose of a marker and a dose of an agent,
obtaining a sample from the subject, and
analyzing the sample for the presence or absence of the marker or a degradation product of the marker,
wherein the marker comprises a prescription or over-the-counter H2 histamine receptor antagonist at a lower than prescription or over-the-counter dose for the H2 histamine receptor antagonist, a metabolite thereof, or a degradation residue thereof and
wherein the marker and the agent are different.
US Pat. No. 10,890,847

PATTERN FORMING METHOD, RESIST PATTERN, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND ELECTRONIC DEVICE

FUJIFILM Corporation, To...

1. A pattern forming method comprising, in this order:forming a film on a substrate, using an active-light-sensitive or radiation-sensitive resin composition containing a resin (A) which has a repeating unit having a phenolic hydroxyl group, and a repeating unit having a group that decomposes by the action of an acid to generate a carboxyl group, and a compound (B) that generates an acid upon irradiation with active light or radiation;
exposing the film; and
developing the exposed film using a developer including an organic solvent, wherein the developer including an organic solvent contains an ester-based organic solvent having 8 or more carbon atoms and 2 or less heteroatoms in the amount of 50% by mass or more, and the ester-based organic solvent contained in the developer does not have an aromatic ring group.
US Pat. No. 10,889,568

INHIBITORS OF TRPC6

Boehringer Ingelheim Inte...

1. A compound selected from the group consisting of any one of compounds selected from the group consisting of:[4-(6-Amino-4-methyl-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone,
[4-(6-Amino-4-methyl-pyridazin-3-yl)-piperidin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2-yl)-methanone,
[4-(6-Amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-fluoro-phenoxy)-4-methoxy-pyridin-2-yl]-methanone,
[4-(6-Amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-trifluoromethyl-phenoxy)-pyridin-2-yl]-methanone,
[4-(6-Amino-4-methoxy-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(4-methoxy-phenoxy)-pyridin-2-yl]-methanone,
[4-(6-Amino-4-ethoxy-pyridazin-3-yl)-piperidin-1-yl]-[4-methoxy-5-(phenoxy)-pyridin-2-yl]-methanone,
5-Ethoxy-6-(1-{4-methoxy-5-[4-(trifluoromethyl)phenoxy]pyridine-2-carbonyl}piperidin-4-yl)pyridazin-3-amine, and
6-(1-{4-Methoxy-5-[4-(trifluoromethyl)phenoxy]pyridine-2-carbonyl}piperidin-4-yl)-5-methylpyridazin-3-amine,
or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,889,824

METHOD FOR GENETIC TRANSFORMATION OF EDIBLE MUSHROOMS

Shanghai Academy of Agric...

1. A method for genetic transformation of Agaricus bisporus, said method comprising:step (a): inoculating Agaricus bisporus liquid mycelia into a foxtail millet grain culture medium, and placing them in a condition of 20-25° C. for pre-culturing until Agaricus bisporus mycelia grow on surfaces of foxtail millet grains, wherein the foxtail millet grain culture medium is shaken up every day during the pre-culturing;
step (b): mixing the foxtail millet grains having the Agaricus bisporus mycelia with an induction culture medium, performing ultrasonic treatment and soaking treatment, discarding the culture medium supernatant, and collecting precipitated foxtail millet grains;
step (c): mixing the foxtail millet grains obtained in step (b) with an Agrobacterium infection liquid containing target genes, performing ultrasonic treatment and static infection, absorbing redundant Agrobacterium bacterial liquid for removal, and performing co-culturing in a condition of 20-25° C., wherein the foxtail millet grains are shaken up every day during the co-culturing; and
step (d): picking, after the co-culturing has ended, individual foxtail millet grains and transferring them to a screening culture medium, and performing screening culturing in a condition of 20-25° C.
US Pat. No. 10,888,543

NEURODEVELOPMENTAL DISORDER THERAPY

ANAVEX LIFE SCIENCES CORP...

1. A method of treating a neurodevelopmental disorder or multiple sclerosis in a subject by administering to a subject in need thereof a composition comprising a therapeutically effective amount of a therapeutic agent selected from the group consisting of Anavex2-73, ANAVEX1-41, Anavex19-144 or any combination thereof, wherein the composition is selected from an oral composition, a transdermal composition and a parenteral composition.
US Pat. No. 10,889,825

COMPOSITIONS AND METHODS THEREOF FOR DOWN-REGULATION OF GENES FOLLOWING ORAL DELIVERY OF AN RNAI MOLECULE BIOENCAPSULATED WITHIN PLANT CELLS

The Trustees of the Unive...

1. A plant cell transformed with a recombinant plant plastid or viral expression vector suitable for stable or transient plant transformation which comprises, as operably linked components in the 5? to 3? direction of translation, a promoter operable in said plant, a heterologous polynucleotide sequence coding for at least one RNAi molecule for downmodulation of Vac ATPase A gene expression and a transcription terminator functional in said plant, wherein said heterologous polynucleotide has high AT content and <60% GC content, and said RNAi molecule is optimized to comprise one or more stem loop structures while lacking complementarity to 3?UTRs in endogenous plant genes, said optimization reducing off target effects relative to RNAi molecules which are not optimized, said vector optionally encoding a nucleic acid encoding a selectable marker, said plant cell further comprising a heterologous polynucleotide sequence coding for an optimized RNAi that down-regulates a P450 monooxygenase gene expression in a second plastid transformation vector.
US Pat. No. 10,888,544

METHODS FOR TREATING GAUCHER DISEASE

GENZYME CORPORATION, Cam...

1. A method of treating Gaucher disease comprising administering to a patient in need thereof an adjusted effective amount of eliglustat, or a pharmaceutically acceptable salt thereof, wherein said patient is an extensive CYP2D6 metabolizer with mild hepatic impairment and wherein said patient is concurrently taking a drug that is strong or moderate CYP3A inhibitor.
US Pat. No. 10,889,826

METHODS AND COMPOSITIONS FOR PRODUCING EPIDERMAL GROWTH FACTOR (EGF) IN SOYBEANS

ARIZONA BOARD OF REGENTS ...

1. A transgenic soybean producing a soluble, bioactive, endoplasmic reticulum (ER)-directed human epidermal growth factor (hEGF) protein, wherein the soybean plant is transformed with an artificial DNA construct to direct EGF production, the construct comprising operably associated components in the 5? to 3? direction of transcription:(a) a promoter that functions in soybean;
(b) a nucleotide sequence that when translated encodes and ER signal peptide comprising SEQ ID NO: 24 operably linked to the 3? end of the promoter;
(c) a polynucleotide operably linked to the 3? end of the sequence encoding the ER-signal peptide, wherein the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 26, or a sequence of at least 95% identical thereto, wherein the polynucleotide encodes a protein having hEGF activity, or a polynucleotide linked to the 3? end of the sequence encoding the ER-signal peptide, wherein the polynucleotide sequence encodes a protein of SEQ ID NO: 12 or a sequence that is at least about 90% identical thereto having hEGF activity;
(d) a nucleotide sequence that when translated encodes an ER retention signal comprising SEQ ID NO: 25; and
(e) a transcriptional termination sequence;wherein the transgenic soybean directly exhibits bioactive hEFG, wherein bioactive hEGF is having hEGF-like activity comprising internalization of epidermal growth factor receptor (EGFR), phosphorylation of EGFR, and/or phosphorylation of AKT.
US Pat. No. 10,889,827

ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USING SAME FOR INCREASING PLANT YIELD AND/OR AGRICULTURAL CHARACTERISTICS

Evogene Ltd., Rehovot (I...

1. A method of increasing yield, growth rate, biomass, vigor, and/or photosynthetic area of a plant, comprising transforming a plant with a heterologous nucleic acid sequence encoding a polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence as set forth in SEQ ID NO: 679, wherein overexpression of said polypeptide in said transformed plant increases yield, growth rate, biomass, vigor, and/or photosynthetic area of the transformed plant.
US Pat. No. 10,890,595

METHOD AND APPARATUS FOR PRE-POSITIONING A RADIALLY SYMMETRIC, COAXIAL SAMPLE WITHIN A SHEATH FLUID TO PROVIDE UNIFORM SAMPLE DELIVERY RATE DURING FLOW

VISIONGATE, INC., Phoeni...

1. A method for pre-positioning a fluid sample in a sheath fluid for dispensing a radially symmetric coaxial sheathed sample into a capillary tube installed in an optical tomography system, the method comprising:obtaining a fluid sample wherein the sample includes a plurality of objects residing in solution;
introducing a sheathed fluid into a sample chamber of an injecting device in fluid communication with the capillary tube, wherein the sample chamber comprises
a focus cone body with an inner bore configured to be preloaded with a sheathed fluid having a selected sample load profile, and
wherein the selected sample load profile has a substantially tear-drop shape;
preloading the sample chamber by dispensing the sample into the sample chamber containing the sheathed fluid in steps as a series of cross-sectional slices, each of the series of cross-sectional slices having substantially the same predetermined thickness;
and
transferring the preloaded sample into the capillary tube; and
wherein the selected sample load profile with cross-sectional slices is calculated by a programmed controller connected to a first motor and a second motor further connected to the sample chamber of an injecting device so as to provide laminar fluid flow regime of the sample fluid flow within the sheathed fluid and to define the tear-drop shape of the sample load profile.
US Pat. No. 10,888,546

PHARMACEUTICAL COMPOSITION

MEXICHEM FLUOR S.A. DE C....

1. A pharmaceutical composition for a metered dose inhaler comprising:a drug component consisting of glycopyrronium bromide, fluticasone propionate and optionally at least one long acting beta-2-agonist selected from the group consisting of indacaterol and indacaterol maleate; and
(ii) a propellant component comprising 1,1-difluoroethane (HFA-152a), wherein the composition contains greater than 0.5 ppm and less than 500 ppm of water based on the total weight of the pharmaceutical composition.
US Pat. No. 10,889,828

TRANSGENIC PLANTS WITH ENHANCED TRAITS

Monsanto Technology LLC, ...

5. A method for increasing yield, increasing nitrogen use efficiency, or increasing water use efficiency in a corn plant comprising: expressing in a corn plant cell a recombinant DNA molecule comprising a nucleotide sequence encoding an inhibitory RNA molecule that targets a gene encoding a protein with at least 95% identity to SEQ ID NO: 22 to suppress expression of said protein; and growing a plant comprising said plant cell.
US Pat. No. 10,889,829

COPY NUMBER VARIANT LEADING TO VIRUS RESISTANCE

RIJK ZWAAN ZAADTEELT EN Z...

1. A method for producing a Cucumis sativus plant resistant to Cucumber Green Mottle Mosaic Virus comprising introducing at least two copies of a combination of two linked RNA-dependent RNA polymerase 1 (RDR1) genes that are inversely oriented into the genome of the plant,wherein the combination of two linked RDR1 genes comprises at least one RDR1 gene that is represented by SEQ ID NO: 1 or has a sequence identity of at least 90% thereof, and at least one RDR1 gene that is represented by SEQ ID NO: 3 or has a sequence identity of at least 90% thereof.
US Pat. No. 10,889,830

BINARY INSECTICIDAL CRY TOXINS

DOW AGROSCIENCES LLC, In...

1. A method for controlling a coleopteran pest which comprises exposing the gut of said coleopteran pest to an effective combination of a potentiator protein and a toxin protein, wherein the potentiator protein comprises a functional amino acid sequence comprising a polypeptide having at least 95% sequence identity to SEQ ID NO:2.
US Pat. No. 10,888,549

PHARMACEUTICAL AGENTS TARGETING CANCER STEM CELLS

The Johns Hopkins Univers...

1. A method for treating cancer in a subject in need thereof comprising administering to the subject an effective amount of a cyclooxygenase-2 (COX 2) inhibitor and a yes-associated protein 1 (YAP 1) inhibitor and wherein the cancer is selected from the group consisting of bladder cancer and urothelial carcinoma.
US Pat. No. 10,889,831

AAV/UPR-PLUS VIRUS, UPR-PLUS FUSION PROTEIN, GENETIC TREATMENT METHOD AND ITS USE IN TREATMENT OF NEURODEGENERATIVE DISEASES, SUCH AS PARKINSON'S DISEASE AND HUNTINGTON'S DISEASE, AMONG OTHERS

UNIVERSIDAD DE CHILE, Sa...

17. A plasmid deposited in the international body of biological deposits, Instituto de Investigaciones Agropecuarias de Chile, INIA, under a deposit number selected from the group consisting of RGM 2231, RGM 2232, RGM 2233, RGM 2234, RGM 2235 and RGM 2236.
US Pat. No. 10,888,550

PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS

Janssen Pharmaceutica NV,...

1. A compound independently selected from the group consisting of:5-(4-((5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)imidazo[1,2-a]pyridine-8-carboxamide;
N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-(8-cyanoimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
N-(5-chloro-6-(1H-pyrazol-1-yl)pyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-N-(6-(methylsulfonyl)-5-(trifluoromethyl)pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
N-(5-chloro-6-(oxazol-2-yl)pyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-(8-methylimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(methylsulfonyl)-1H-pyrazole-4-carboxamide;
N-(5-chloro-6-(5-methyloxazol-2-yl)pyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
N-(5-chloro-6-(4-methyloxazol-2-yl)pyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
1-(7-cyanopyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide;
4-(5-(trifluoromethyl)-4-((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyridine-7-carboxamide;
N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-(7-cyanopyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
1-(7-chloropyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide;
N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-(7-chloropyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
4-(4-((5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)carbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyridine-7-carboxamide;
(*S)—N-(5-chloro-6-(1-methoxyethyl)pyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*R)—N-(5-chloro-6-(tetrahydrofuran-2-yl)pyridin-3-yl)-1-(8-chloroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*R)—N-(5-chloro-6-(1-methoxyethyl)pyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*S)—N-(5-chloro-6-(tetrahydrofuran-2-yl)pyridin-3-yl)-1-(8-chloroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*S)—N-(5-chloro-6-(tetrahydrofuran-2-yl)pyridin-3-yl)-1-(7-chloropyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*R)—N-(5-chloro-6-(tetrahydrofuran-2-yl)pyridin-3-yl)-1-(7-chloropyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*S)—N-(5-chloro-6-(tetrahydrofuran-2-yl)pyridin-3-yl)-1-(7-cyanopyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*R)—N-(5-chloro-6-(tetrahydrofuran-2-yl)pyridin-3-yl)-1-(7-cyanopyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*S)—N-(5-chloro-6-(1-methoxyethyl)pyridin-3-yl)-1-(7-cyanopyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*R)—N-(5-chloro-6-(1-methoxyethyl)pyridin-3-yl)-1-(7-cyanopyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*S)—N-(5-chloro-6-(1-methoxyethyl)pyridin-3-yl)-1-(7-chloropyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
(*R)—N-(5-chloro-6-(1-methoxyethyl)pyridin-3-yl)-1-(7-chloropyrazolo[1,5-a]pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
N-(6-((dimethyl(oxo)-?6-sulfanylidene)amino)-5-methylpyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
N-(6-((dimethyl(oxo)-?6-sulfanylidene)amino)-5-(trifluoromethyl)pyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-N-(6-(S-methylsulfonimidoyl)-5-(trifluoromethyl)pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
N-(6-((dimethyl(oxo)-?6-sulfanylidene)amino)-5-fluoropyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
and
N-(5-chloro-6-((dimethyl(oxo)-?6-sulfanylidene)amino)pyridin-3-yl)-1-(8-fluoroimidazo[1,2-a]pyridin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
or an enantiomer, diastereomer, or a pharmaceutically acceptable salt form thereof.
US Pat. No. 10,889,832

GENE THERAPY FOR TREATING FAMILIAL HYPERCHOLESTEROLEMIA

The Trustees of the Unive...

1. A pharmaceutical composition suitable for peripheral vein infusion in human subjects, comprising a suspension of replication deficient recombinant adeno-associated virus (rAAV) in a formulation buffer, wherein:(a) the rAAV comprises a vector genome comprising AAV ITRs and a nucleic acid sequence encoding a human LDL receptor (hLDLR) operably linked to a liver specific promoter, said vector genome packaged in an AAV8 capsid;
(b) the formulation buffer comprises an aqueous solution of phosphate buffered saline and a poloxamer, wherein the formulation buffer is at a pH 7 to 7.5; and
(c) one or more of:
(i) the rAAV Genome Copy (GC) titer is at least 1×1013 GC/ml;
(ii) the rAAV is at least about 95% free of empty capsids as determined by oqPCR or ddPCR;
(iii) the rAAV Empty:Full particle ratio is between 0:4 to 1:4; and
(iv) a dose of 5×1011 GC/kg of the rAAV suspension decreases baseline cholesterol levels in a double knockout (DKO) LDLR?/?Apobec?/? mouse model of Homozygous Familial Hypercholesterolemia (HoFH) by 25% to 75% as determined at day 14 post-treatment with the rAAV suspension.
US Pat. No. 10,889,833

RATIONAL POLYPLOID ADENO-ASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF DISEASE

The University of North C...

1. A substantially homogenous population of adeno-associated virus (AAV) virions having at least two viral structural proteins from the group consisting of AAV capsid proteins VP1, VP2, and VP3, wherein the at least two viral structural proteins are sufficient to form an AAV virion that encapsidates an AAV genome, and wherein at least one of the at least two viral structural proteins present is from a single AAV serotype and is from a completely different serotype than the other viral structural protein, and wherein the VP1 is only from one serotype, the VP2 is only from one serotype, and the VP3 is only from one serotype, wherein the virions comprise a heterologous gene that encodes a protein to treat a disease or disorder, wherein the disease or disorder is hemophilia A, hemophilia B, diabetes mellitus, cancer, arthritis, muscle wasting, heart disease, a neurological disease or disorder, an autoimmune disease, a skeletal muscle disease, cystic fibrosis, thalassemia, phenylketonuria, LDL receptor deficiency, hyperammonemia, anemia, arthritis, a retinal degenerative disorder, or adenosine deaminase deficiency.
US Pat. No. 10,888,552

TREATMENT OF DISORDERS OF SEXUAL AROUSAL WITH LOCAL APPLICATION OF AGENTS THAT INCREASE MEMBRANE EXCITABILITY

Steven Rothman, Clayton,...

1. A method for treating sexual dysfunction in a subject in need thereof or for stimulating erogenous zones of a subject in need thereof, the method comprising: topically applying to the subject's genitalia a composition consisting essentially of: a potassium channel blocker selected from the group consisting of 4-aminopyridine; 3,4-diaminopyridine, quinidine ((S)-(6-Methoxyquinolin-4-yl)[(1S,2R,4S,5R)-5-vinylquinuclidin-2-yl]methanol), ibutilide (N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide), propafenone (1-{2-[2-Hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one), amiodarone ((2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine), vernakalant ((3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl) ethoxy]cyclohexyl}pyrrolidin-3-ol), dofetilide (N-[4-(2-{[2-(4-methane sulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide), dronedarone (N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide), and combinations thereof and a lubricant selected from the group consisting of glycerin, hydroxyethyl cellulose, xylitol, carrageenan, and combinations thereof; wherein the composition is a topical composition.
US Pat. No. 10,889,834

METHODS AND COMPOSITIONS FOR ENHANCING TARGETED TRANSGENE INTEGRATION

Sangamo Therapeutics, Inc...

1. A method of integrating a transgene encoding a protein in a forward orientation into a selected endogenous genomic locus of an isolated population of liver or hematopoietic stem cells, the method comprising:treating the isolated liver or hematopoietic stem cells with at least one topoisomerase inhibitor, the at least one topoisomerase inhibitor comprising camptothecin or etoposide;
introducing an AAV vector into the treated population of isolated liver or hematopoietic stem cells, the AAV vector comprising regions of homology to the selected endogenous genomic locus flanking the transgene, wherein the population of liver or hematopoietic stem cells is grown in the presence of the at least one topoisomerase inhibitor, such that the transgene is integrated into the selected endogenous locus in a forward orientation and expression of the transgene is driven an endogenous promoter and further wherein the transgene is integrated into the selected endogenous genomic locus and the protein is expressed from the endogenous promoter at levels increased at least 5-fold as compared to cells not grown in the presence of the at least one topoisomerase inhibitor.
US Pat. No. 10,889,835

PRODUCTION OF MONOTERPENE BLENDS BY UNICELLULAR PHOTOSYNTHETIC MICROORGANISMS

The Regents of the Univer...

1. A method of obtaining a blend of monoterpene hydrocarbons from cyanobacteria in which ?-myrcene is the predominant monoterpene, the method comprising:culturing a cyanobacteria strain that has been genetically modified to express a heterologous Picea sitchensis ?-phellandrene synthase as a fusion protein with a cyanobacteria CpcB polypeptide that has at least 95% identity to a wild type cyanobacteria CpcB polypeptide, wherein the heterologous Picea sitchensis ?-phellandrene synthase has at least 95% identity to SEQ ID NO: 8 and is encoded by a polynucleotide comprising a Picea sitchensis ?-phellandrene synthase nucleic acid sequence that is codon-optimized for expression in cyanobacteria, and is fused to the 3? end of a leader nucleic acid sequence encoding the cyanobacteria CpcB polypeptide;
isolating a blend of monoterpene hydrocarbons comprising ?-myrcene, ?-phellandrene, ?-phellandrene, and ?-pinene, produced in the cyanobacteria that has spontaneously diffused from the cyanobacteria intracellular space into the culture medium;
analyzing the levels of monoterpenes present in the monoterpene blend; and
determining that ?-myrcene is the predominant monoterpene present in the blend of monoterpenes.
US Pat. No. 10,889,836

YEAST FOR ETHANOL PRODUCTION

Microbiogen Pty. Ltd., S...

1. A Saccharomyces cerevisiae yeast strain, wherein the strain is Saccharomyces cerevisiae strain MBG4985 (deposited under Accession No. NRRL Y67342 at the Agricultural Research Service Patent Culture Collection (NRRL), Northern Regional Research Center, 1815 University Street, Peoria, Ill., USA).
US Pat. No. 10,888,555

PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE FOR BENEFICIALLY INFLUENCING BLOOD LIPID LEVELS BY MODIFYING THE INTESTINAL MICROBIOTA

CONARIS RESEARCH INSTITUT...

1. A pharmaceutical composition for beneficially influencing blood and/or plasma and/or serum lipid levels by beneficially modifying the intestinal microbiota, comprising an active substance selected from nicotinic acid, nicotinamide, nicotinic acid esters, and combinations of any two or more thereof, wherein the composition is formulated for oral administration with controlled and/or delayed release for selective local release of the active substance for topical efficacy in the lower small intestine and/or colon where the intestinal microbiota to be modified are located, thereby beneficially modifying the intestinal microbiota, in an amount effective to increase high density lipoprotein (HDL) blood levels, decrease liver fat content, and/or beneficially influence blood and/or plasma and/or serum lipid levels, wherein the composition is provided with a coating and wherein the controlled and/or delayed release is achieved by the coating.
US Pat. No. 10,889,837

CORN BLENDS THAT INCLUDE HIGH OIL CORN AND METHODS OF MAKING ONE OR MORE BIOCHEMICALS USING HIGH OIL CORN OR CORN BLENDS THAT INCLUDE HIGH OIL CORN

POET Research, Inc., Sio...

1. A method of producing a biochemical and corn oil from corn, the method comprising:milling a whole corn grain blend to provide a feedstock comprising corn starch and corn oil, wherein the whole corn grain blend comprises a corn grain blend having an average oil content of greater than 4 percent on a dry weight basis of the corn grain blend, wherein the corn grain blend comprises a first corn grain having an oil content of 4 percent or less on a dry weight basis and a second corn grain having an oil content of at least 6 percent on a dry weight basis; wherein the first corn grain comprises #2 yellow dent corn grain and the second corn grain comprises an amount of at least 5 percent of the corn grain blend;
adding water to at least a portion of the feedstock to form a first aqueous composition comprising corn starch and corn oil;
enzymatically hydrolyzing at least a portion of the starch in the first aqueous composition to produce a second aqueous composition comprising glucose and corn oil;
fermenting the second aqueous composition to produce a third aqueous composition comprising the biochemical and corn oil, wherein the second composition comprises a microorganism that can ferment the glucose into the biochemical; and
recovering biochemical and corn oil after fermentation.
US Pat. No. 10,888,556

METHOD FOR TREATING MYOPIA WITH AN NSAID AND AN ANTI-MUSCARINIC AGENT

Kaohsiung Chang Gung Memo...

1. A method for treating myopia, comprising the step of administering an effective amount of NSAID to a myopic subject in need thereof.
US Pat. No. 10,888,557

OPHTHALMIC COMPOSITION

SYDNEXIS, INC., Del Mar,...

1. A method of treating progression of myopia or reducing the progression rate of myopia in an individual in need thereof, comprising administering to an eye of the individual (a) an aqueous solution comprising atropine or atropine sulfate and less than about 10% of a degradant of atropine or atropine sulfate formed from degradation of the atropine or atropine sulfate and (b) a buffering agent.
US Pat. No. 10,889,839

BIOSYNTHETIC ORGANISMS WITH ENHANCED CARBON UTILIZATION

INVISTA North America S.a...

1. A nonnaturally occurring organism which exhibits increased carbon utilization, said nonnaturally occurring organism being a Cupriavidus species and comprising disruption in a one or more cbbX genes leading to increased carbon utilization as compared to an organism without the disruption.
US Pat. No. 10,889,840

CONVERSION OF METHYLGLYOXAL INTO HYDROXYACETONE USING NOVEL ENZYMES AND APPLICATIONS THEREOF

METABOLIC EXPLORER, Sain...

1. A method for the fermentative conversion of methylglyoxal into hydroxyacetone, comprising the step of expressing, in a microorganism, at least one methylglyoxal reductase having a catalytic efficiency kcat/Km equal or superior to 5 mM?1s?1 wherein said methylglyoxal reductase is selected from the group consisting of YjgB having the sequence of SEQ ID NO: 1, YjgB* (N240Y) having the sequence of SEQ ID NO: 9, YigB*(I165V) having the sequence of SEQ ID NO: 125 and YigB*(Q39R/I165V/A296V) having the sequence of SEQ ID NO: 127.
US Pat. No. 10,888,816

PROCESS FOR PRODUCING A PURIFIED GAS STREAM

Shell Oil Company, Houst...

1. A process for removing hydrogen sulfide and carbon dioxide from a feed gas stream, the process comprising the following steps:(i) converting hydrogen sulfide in the feed gas stream to elemental sulfur and a gas stream, wherein step (i) comprises:
(ia) converting hydrogen sulfide in the feed gas stream to elemental sulfur in a Claus unit, thereby obtaining elemental sulfur and a first gas stream comprising a reduced amount of hydrogen sulfide and carbon dioxide, wherein the feed gas stream comprises up to 25 vol % of carbon dioxide;
(ib) removing additional hydrogen sulfide from the first gas stream produced in step (ia) by means of a solvent comprising an amine, thereby obtaining the gas stream comprising a further reduced amount of hydrogen sulfide relative to the first gas stream; and
(ii) contacting at least a part of the gas stream obtained in step (ib) with an aqueous lean absorbing medium in an absorption zone to absorb the carbon dioxide and to obtain a carbon dioxide lean treated gas stream and spent absorbing medium;
wherein a pressure in the absorption zone used in step (ii) is in a range of between 0.9 and 2 bara; and
wherein the aqueous lean absorbing medium used in step (ii) comprises one or more amines chosen from:
diethylenetriamine (DETA), triethylenetetramine (TETA), tetraethylenepentamine (TEPA), and mixtures thereof,
N-(2-hydroxyethyl)piperazine.
US Pat. No. 10,889,841

OLEAGINOUS YEAST VARIANT, METHOD FOR OBTAINING THEREOF AND USE THEREOF FOR LIPID PRODUCTION

ENI S.p.A., Rome (IT)

1. A method for obtaining an oleaginous yeast variant, comprising:i. exposing one or more cells of an oleaginous yeast strain to a mutagenic agent in order to generate random mutations in genomic DNA of the cells;
ii. inoculating and cultivating in a culture medium the cells treated with the mutagenic agent, wherein the culture medium comprises a carbon source at a concentration from 20 g/L to 100 g/L, wherein at least one nitrogen source is present; and
iii. separating yeast cells having a lower density from the cell culture;
wherein step (iii) of said method comprises the sub-steps of:
a) collecting a sample from the culture and adding at least one thickening agent in a suitable amount, to obtain a cell suspension;
b) centrifuging the cell suspension for a time of 1 to 5 minutes at an acceleration of 500 g to 1000 g, to obtain a centrifugation supernatant;
c) collecting a higher fraction of the centrifugation supernatant in order to isolate one or more cells characterized by lower density from the rest of the cell culture;
d) inoculating and cultivating the fraction of the supernatant isolated in c) in a culture medium, comprising a carbon source at a concentration from 20 g/L to 100 g/L, wherein at least one nitrogen source is present at a concentration from 3 g/L to 40 g/L;
e) repeating a) to d) at least 2 times, and
f) isolating one or more single mutant colonies,
and wherein the sub-step a) is carried out by adding sorbitol to the culture sample, as a thickening agent, up to a concentration of 1M to 3M.
US Pat. No. 10,889,842

MICROORGANISMS FOR THE ENHANCED PRODUCTION OF AMINO ACIDS AND RELATED METHODS

CALYSTA, INC., Menlo Par...

1. A recombinant C1 metabolizing microorganism, comprising:(a) a first heterologous nucleic acid selected from
(i) a heterologous nucleic acid that encodes an L-amino acid biosynthesis enzyme for producing a desired amino acid selected from L-lysine, L-tryptophan, L-methionine, L-cysteine, L-threonine, L-histidine, and L-valine, and
(ii) a heterologous nucleic acid comprising an expression control sequence that is operably linked to a nucleic acid that encodes a native L-amino acid biosynthesis enzyme for producing the desired amino acid, and
(b) a second heterologous nucleic acid that encodes a cache polypeptide that comprises at least 70 amino acid residues in length and comprises the desired amino acid at a level that is 10% or more of the total number of amino acid residues in the cache polypeptide;
wherein the recombinant C1 metabolizing microorganism is capable of converting a natural gas-derived carbon feedstock into the desired L-amino acid at an increased level as compared to the non-genetically engineered C1 metabolizing microorganism,
wherein a ?13C value of the recombinant C1 metabolizing microorganism is less than ?30‰, and
wherein
when the desired amino acid is L-lysine, the L-amino acid biosynthesis enzyme of (a) (i) or the native L-amino acid biosynthesis enzyme of (a) (ii) is a lysine biosynthesis enzyme, and the cache polypeptide of (b) comprises lysine at a level that is 10% or more of the total number of amino acid residues in the cache polypeptide of (b),
when the desired amino acid is L-tryptophan, the L-amino acid biosynthesis enzyme of (a) (i) or the native L-amino acid biosynthesis enzyme of (a) (ii) is a tryptophan biosynthesis enzyme, and the cache polypeptide of (b) comprises tryptophan at a level that is 10% or more of the total number of amino acid residues in the cache polypeptide of (b),
when the desired amino acid is L-methionine, the L-amino acid biosynthesis enzyme of (i) or the native L-amino acid biosynthesis enzyme of (ii) is a methionine biosynthesis enzyme, and the cache polypeptide of (b) comprises methionine at a level that is 10% or more of the total number of amino acid residues in the cache polypeptide of (b),
when the desired amino acid is L-cysteine, the L-amino acid biosynthesis enzyme of (i) or the native L-amino acid biosynthesis enzyme of (ii) is a cysteine biosynthesis enzyme, and the cache polypeptide of (b) comprises cysteine at a level that is 10% or more of the total number of amino acid residues in the cache polypeptide of (b),
when the desired amino acid is L-threonine, the L-amino acid biosynthesis enzyme of (i) or the native L-amino acid biosynthesis enzyme of (ii) is a threonine biosynthesis enzyme, and the cache polypeptide of (b) comprises threonine at a level that is 10% or more of the total number of amino acid residues in the cache polypeptide of (b),
when the desired amino acid is L-histidine, the L-amino acid biosynthesis enzyme of (i) or the native L-amino acid biosynthesis enzyme of (ii) is a histidine biosynthesis enzyme, and the cache polypeptide of (b) comprises histidine at a level that is 10% or more of the total number of amino acid residues in the cache polypeptide of (b), and
when the desired amino acid is L-valine, the L-amino acid biosynthesis enzyme of (i) or the native L-amino acid biosynthesis enzyme of (ii) is a valine biosynthesis enzyme, and the cache polypeptide of (b) comprises valine at a level that is 10% or more of the total number of amino acid residues in the cache polypeptide of (b).
US Pat. No. 10,889,587

TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE

SPERO THERAPEUTICS, INC.,...

1. A crystalline tebipenem pivoxil hydrobromide salt form, wherein the XPRD of the form, obtained from a Cu K? source, has the characteristic 20 values of FIG. 14.
US Pat. No. 10,889,843

CORYNEBACTERIUM SP. MICROORGANISMS HAVING L-LYSINE-PRODUCING ABILITY AND L-LYSINE PRODUCING METHOD USING SAME

CJ Cheiljedang Corporatio...

1. A modified microorganism of the genus Corynebacterium, wherein a protein comprising the amino acid sequence of SEQ ID NO: 1 is inactivated; and having enhanced expression of one or more genes selected from the group consisting of aspB (aspartate aminotransferase-encoding gene) lysC (aspartate kinase-encoding gene), asd (aspartate semialdehyde dehydrogenase-encoding gene), dapA (dihydrodipicolinate synthase-encoding gene), dapB (dihydrodipicolinate reductase-encoding gene) and lysA (diaminodipimelate decarboxylase-encoding gene).
US Pat. No. 10,889,844

METHODS OF DEGRADING OR HYDROLYZING A POLYSACCHARIDE

Novozymes, Inc., Davis, ...

1. A process for producing a fermentation product, comprising:(a) saccharifying a cellulosic material with an enzyme composition comprising a GH61 protein and one or more enzymes selected from the group consisting of an endoglucanase, a cellobiohydrolase, a beta-glucosidase, and a CBM33, wherein the saccharifying is carried out in the presence of at least one reducing agent and at least one divalent metal ion, wherein the at least one reducing agent is selected from the group consisting of ascorbic acid, coumaric acid, ferulic acid, gallic acid, glucose, glucosamine, N-acetylglucosamine, reduced glutathione, humic acid, succinic acid, and lignin or fragments thereof, wherein the at least one divalent metal ion is selected from the group consisting of Ca2+, Co2+, Cu2+, Mg2+, Mn2+, Ni2+, and Zn2+, and wherein the saccharifying of the cellulosic material is increased by the presence the GH61 protein in combination with the at least one reducing agent and the at least one divalent metal ion relative to without the combination;
(b) fermenting the saccharified cellulosic material with one or more fermenting microorganisms to produce the fermentation product; and
(c) recovering the fermentation product from the fermentation.
US Pat. No. 10,889,845

PRODUCTION OF N-GLYCOPROTEINS FOR ENZYME ASSISTED GLYCOMODIFICATION

UNIVERSITY OF COPENHAGEN,...

1. A mammalian cell comprising one or more glycosyltransferase genes that have been partially or fully inactivated, and that has more homogeneous glycosylation capacities, wherein Alpha-1,6-Mannosyl-Glycoprotein 2-Beta-N-Acetylglucosaminyltransferase (mgat2) has been knocked out (KO), and, optionally wherein Alpha-1,3-Mannosyl-Glycoprotein 4-Beta-N-Acetylglucosaminyltransferase (mgat4A) and/or Alpha-1,3-Mannosyl-Glycoprotein 4-Beta-N-Acetylglucosaminyltransferase B (mgat4B) and/or Alpha-1,6-Mannosylglycoprotein 6-Beta-N-Acetylglucosaminyltransferase (mgat5) has been KO, allowing production of N-glycans with monoantennary structure, and further comprising KO of at least one sialyltransferase and KO of a UDP-G1cNAc:betaGa1 beta-1,3-N-acetylglucosaminyltransferase 2 (B3 gnt2) gene, allowing production of N-glycans with monoantennary structure and without sialic acid capping and without Poly-N-acetyllactosamine (poly-LacNAc).
US Pat. No. 10,888,821

METHOD FOR TREATING A MICROPOROUS MEMBRANE

PPG Industries Ohio, Inc....

1. A method for treating a surface of a microporous membrane, the membrane comprising a polyolefinic polymeric matrix; finely divided particulate, substantially water-insoluble inorganic filler distributed throughout the matrix; and a network of interconnecting pores communicating throughout the microporous membrane,the method comprising:
(1) contacting at least one surface of the membrane with a treatment composition comprising:
(a) an acrylic polymer prepared from a mixture of vinyl monomers comprising: (i) a (meth)acrylic acid monomer and (ii) a silane-functional acrylic monomer; and
(b) a base,
wherein the acrylic polymer is in contact with the filler present in the matrix; and
(2) subjecting the membrane of (1) to conditions sufficient to effect a condensation reaction between the filler and the acrylic polymer.
US Pat. No. 10,888,822

SEPARATION MEMBRANE

Toray Industries, Inc., ...

1. A reverse osmosis membrane consisting essentially of a cellulose ester, having a tensile elasticity of 1,500 to 6,500 MPa and a salt rejection of 90.0% or more, having a degree of orientation of 1.30 to 2.50 in a lengthwise direction of the reverse osmosis membrane, and having a crystal melting heat amount (?Hm) of 6 to 10 J/g in a temperature rise measurement with a differential scanning calorimeter (DSC).
US Pat. No. 10,889,847

KIT AND DISCS FOR USE IN DISC DIFFUSION ANTIBIOTIC SENSITIVITY TESTING

Yissum Research Developme...

1. A tolerance diffusion kit for measuring tolerance or persistence of a microorganism to one or more antimicrobial agents, comprising:a) several disks containing one or more antimicrobial agents or one antimicrobial agent at different concentrations;
b) at least one growth promoting agent provided on a growth promoting disk or as a solution in a vial;
c) instructions for use of the tolerance diffusion kit;
d) one or more microorganism growth plates; and
e) means for detecting (i) at least one inhibition zone around said disks containing one or more antimicrobial agents or one antimicrobial agent at different concentrations, and (ii) the appearance of any microorganism colony within each detected inhibition zone.
US Pat. No. 10,888,567

INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY

Auckland UniServices Limi...

1. 6-chloro-5-fluoroisoxazolo [5,4-b]pyridin-3-amine or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,888,824

METHODS FOR TREATING FILLED MICROPOROUS MEMBRANES

PPG Industries Ohio, Inc....

1. A method for treating a surface of a microporous membrane, the membrane comprisinga polyolefinic polymeric matrix, wherein the polyolefinic polymeric matrix consists essentially of a polyolefin selected from the group consisting of ultrahigh molecular weight polyethylene, ultrahigh molecular weight polypropylene, high density polyethylene, high density polypropylene, and mixtures thereof;
a finely divided particulate, substantially water-insoluble inorganic filler distributed throughout the polyolefinic polymeric matrix, wherein the inorganic filler is selected from the group consisting of silica, alumina, calcium oxide, zinc oxide, magnesium oxide, titanium oxide, zirconium oxide, and mixtures thereof; and a
network of interconnecting pores communicating throughout the microporous membrane,
the method comprising in sequence:
(1) contacting at least one surface of the membrane with a treatment composition comprising a silane-functional polyamine compound having at least one alkoxy silane group, wherein the treatment composition comprises (i) an acidic aqueous composition, or (ii) a basic aqueous composition, such that the silane-functional polyamine compound is in intimate contact with the filler present in the polyolefinic polymeric matrix; and
(2) effecting a condensation reaction between the inorganic filler which is distributed throughout the polyolefinic polymeric matrix and the silane-functional polyamine compound (i) by subjecting the membrane of (1) to ambient temperature for a time sufficient to effect the condensation reaction, and/or (ii) by subjecting the membrane of (1) to temperatures ranging from 50° C. to 145° C.
US Pat. No. 10,889,849

OXIDIZED GLUTATHIONE ASSAY

PROMEGA CORPORATION, Mad...

1. A method for determining GSH:GSSG ratio in a sample, the method comprising:(a) providing a first portion of the sample and a second portion of the sample;
(b) contacting the first portion of the sample with a sulfhydryl modifying agent to provide a modified first sample portion;
(c) adding to the modified first sample portion an excess of a reducing agent, glutathione-S-transferase, and a substrate for a glutathione-S-transferase, which is converted to a signal-generating compound in the presence of GSH and glutathione-S-transferase, wherein the reducing agent inactivates the sulfhydryl alkylating agent and reduces any GSSG to GSH, to form a first solution;
(d) measuring the signal of the first solution, wherein neither the inactivated sulfhydryl alkylating agent nor the reducing agent is removed from the first solution;
(e) contacting the second portion of the sample with glutathione-S-transferase and a substrate for a glutathione-S-transferase, which is converted to a signal-generating compound in the presence of GSH and glutathione-S-transferase to form a second solution;
(f) measuring the signal of the second solution; and
(g) comparing the signal of the second solution to the signal of the first solution to determine the GSH:GSSG ratio.
US Pat. No. 10,888,568

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER USING PHENOTHIAZINE

National Yang Ming Univer...

1. A method for treating human non-small-cell lung cancer (NSCLC) in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (S)-thioridazine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier wherein the pharmaceutical composition is free of (R)-thioridazine.
US Pat. No. 10,889,594

MCL-1 INHIBITORS AND METHODS OF USE THEREOF

AstraZeneca AB, Sodertal...

1. A compound which is Form A (Ra)-17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid monohydrate.
US Pat. No. 10,889,850

METHODS FOR IMPROVED ISOLATION OF GENOMIC DNA TEMPLATES FOR ALLELE DETECTION

Avellino Lab USA, Inc., ...

1. A method for preparing genomic DNA (gDNA) samples, the method comprising:(A) providing a sample of buccal epithelial cells from a subject, the buccal epithelial cells adhered to at least a part of a substrate;
(B) agitating, for no more than 120 seconds, said at least a part of the substrate with the adhered epithelial cells in a first lysis solution capable of lysing buccal cells adhered to the substrate;
(C) removing the substrate from the first lysis solution;
(D) performing an extraction incubation of gDNA in the first lysis solution by incubating the first lysis solution at a temperature between 35° C. and 55° C. for an incubation time between 15 minutes and 120 minutes after removing (C) the substrate from the first lysis solution to prepare a first gDNA sample;
(E) agitating said at least a part of the substrate, after removing the substrate from the first lysis solution, in a second lysis solution capable of lysing buccal cells adhered to the substrate;
(F) removing the substrate from the second lysis solution; and
(G) performing an extraction incubation of second gDNA in the second lysis solution by incubating the second lysis solution at a temperature between 35° C. and 55° C. for an incubation time between 15 minutes and 120 minutes after removing (F) the substrate from the second lysis solution to prepare a second gDNA sample.
US Pat. No. 10,888,056

TOMATO FRUIT HAVING INCREASED FIRMNESS

Syngenta Participations A...

1. A method for selecting a cultivated Solanum lycopersicum plant that provides fruit with increased firmness of the inner pericarp as compared with fruit from a control Solanum lycopersicum plant, the method comprising:a) detecting in the cultivated Solanum lycopersicum plant the presence of QTL2 on chromosome 2, and
b) selecting a cultivated Solanum lycopersicum plant that includes the presence of said QTL2, thereby selecting a cultivated Solanum lycopersicum plant that provides fruit with increased firmness of the inner pericarp as compared with fruit from a control Solanum lycopersicum plant;
wherein detecting the presence of said QTL2 in the cultivated Solanum lycopersicum plant comprises:
i) providing a sample of genomic DNA from the cultivated Solanum lycopersicum plant, and
ii) detecting in the sample of genomic DNA at least one DNA marker including HOX7A, wherein HOX7A can be detected by a forward primer of SEQ ID NO: 7 and a reverse primer of SEQ ID NO: 8; and
wherein the increased fruit firmness of the inner pericarp is from between 1.2 to 2 times greater at the harvesting stage than that of fruit from the control Solanum lycopersicum plant.
US Pat. No. 10,888,569

METHODS AND COMPOSITIONS FOR TREATING CANCER

The University of Chicago...

1. A method for reducing or ameliorating metformin-resistant triple negative breast cancer (TNBC) tumor growth in a subject comprising administering an effective amount of hemin and metformin to the subject.
US Pat. No. 10,889,851

METHOD FOR MOVING A PROCESSING VIAL BETWEEN LOCATIONS OF AN INSTRUMENT

Gen-Probe Incorporated, ...

1. A method for moving a fluid-containing processing vial between locations of an instrument, the method comprising the automated steps of:(a) dispensing a fluid into a processing vial, the fluid being dispensed with a pipette tip engaged in a frictional fit with a probe of a pipettor;
(b) after step (a), stripping the pipette tip from the probe of the pipettor;
(c) inserting the probe of the pipettor into an open top end of a cap, thereby engaging the cap in a frictional fit;
(d) while the cap is engaged by the probe of the pipettor, inserting a closed lower end of the cap into an open top end of the processing vial to thereby form a cap/vial assembly, wherein the cap is coupled to the processing vial and the processing vial is sealed by the cap;
(e) with the pipettor, moving the cap/vial assembly from a first location of an instrument, where the cap/vial assembly is formed, to a second location of the instrument; and
(f) at the second location of the instrument, ejecting the cap/vial assembly from the probe of the pipettor, thereby depositing the cap/vial assembly at the second location.
US Pat. No. 10,888,057

BUGLOSSOIDES ‘TRAFALGAR’

NIAB Trading LTD.

1. A Buglossoides arvensis plant named ‘Trafalgar’, representative seed deposited at the NCIMB in Aberdeen, Scotland and accorded International Depository Authority Accession No. NCIMB-43564.
US Pat. No. 10,888,570

SPIRONOLACTONE AQUEOUS COMPOSITIONS

CMP DEVELOPMENT LLC, Far...

1. A ready-to-use liquid formulation, comprising:(a) about 0.20% w/v to about 1.0% w/v of spironolactone;
(b) from about 0.18% w/v to about 0.36% w/v of a xanthan gum;
(c) a pharmaceutically acceptable excipient; and
(d) a sufficient amount of a water vehicle;
wherein the formulation exhibits a content uniformity of about 100% labeled content after shaking the formulation for about 10 seconds.
US Pat. No. 10,888,571

METHOD AND COMPOSITION FOR INCREASING MUSCLE PROTEIN SYNTHESIS AND/OR FUNCTIONAL STRENGTH IN MAMMALS

Lonza Consumer Health Inc...

1. A method for preserving muscle mass and function by increasing skeletal muscle protein synthesis and/or decreasing skeletal muscle protein degradation in healthy mammals, the method comprising administering to the healthy mammal a protein building composition, said protein building composition comprising an amino acid derivative, wherein the amino acid derivative is L-carnitine, derivatives of L-carnitine, and/or salts thereof, combined with an amino acid component, wherein the amino acid component is Leucine, metabolites of Leucine, and/or salts thereof, and a nitrogenous organic acid, wherein the nitrogenous organic acid is Creatine, derivatives and/or analogs of Creatine, or salts thereof;wherein the protein building composition is administered in an amount sufficient to increase skeletal muscle protein synthesis, increase functional strength, or increase both skeletal muscle protein synthesis and functional strength, without requiring the healthy mammal to participate in physical activity; and
wherein the nitrogenous organic acid is present in the protein building composition at a concentration of about 30% to about 80% by mass based on the mass of the amino acid derivative, amino acid component, and nitrogenous organic acid, and the amino acid component is present in the protein building composition at a concentration of about 20% to 30.8% by mass based on the mass of the amino acid derivative, amino acid component, and nitrogenous organic acid.
US Pat. No. 10,889,853

RNA MICROARRAY FOR DETECTING INTERACTION BETWEEN PROTEIN AND RNA CONTAINING A HIGHER-ORDER STRUCTURE

KYOTO UNIVERSITY, Kyoto ...

1. A method for detecting RNA which binds to a protein, comprising the following steps:(1) a step of bringing a multiplicity of RNA probes into contact with a target protein,
wherein each RNA probe in the multiplicity of RNA probes comprises:
(i) a complementary strand sequence to each respective DNA barcode sequence in a multiplicity of DNA barcode sequences;
(ii) a double stranded stem structure comprising a first stem portion complementary to and hybridized with a second stem portion; and
(iii) a sequence of a loop portion linking said first and second stem portions,
wherein each RNA probe is hybridized to each respective complementary DNA barcode sequence in the multiplicity of DNA barcode sequences; and wherein a combination of the sequence (i) and (iii) is different in the multiplicity of RNA probes so that each of the sequence (iii) in the multiplicity of RNA probes sequence can be identified by the corresponding sequence (i), and the sequence (ii) has a common sequence in the multiplicity of RNA probes,
wherein the multiplicity of DNA barcode sequences is selected from a tag, a zip code, an orthonormal sequence or a barcode sequence so as to prevent cross-hybridization reaction;
(2) a step of isolating the target protein bound to an RNA probe obtained in step (1) while maintaining binding to the RNA probe,
(3) a step of extracting the RNA probe from the target protein obtained in step (2),
(4) a step of bringing the RNA probe obtained in step (3) into contact with a slide having the multiplicity of DNA barcode sequences attached thereto,
(5) a step of identifying the RNA probe hybridized with the slide, and
(6) a step of detecting RNA containing the sequence (iii) contained in the RNA probe identified in step (5) as the RNA which binds to the target protein.
US Pat. No. 10,888,572

DIETARY AND NUTRITIONAL COMPOSITIONS AND METHODS OF USE

BIO-UP MIMETIC TECHNOLOGI...

1. A composition, comprising a stable homogeneous dispersion, comprising:a liposomal vesicle composition having a lecithin bilayer and an aqueous phase, the liposomal vesicle composition, comprising:
a lecithin from oil-bearing seeds having phosphatidylethanolamine (PE), phosphatidylinositol (PI), and 20 to 70 w/w % phosphatidylcholine (PC);
a lipophilic active ingredient incorporated within the lecithin bilayer of the liposomal vesicle;
a triglyceride source incorporated within the lecithin bilayer of the liposomal vesicle; and
conditioned water, the conditioned water having less than 100 parts per million (ppm) hard ions or having a conductivity of less than 20 microSiemens per centimeter.
US Pat. No. 10,889,854

SYSTEM AND METHOD FOR IMMOBILIZATION FREE ELECTROCHEMILUMINESCENCE DNA DETECTION USING A LUMINOPHORE DYE FOR MULTI-SPECIES DETECTION

UNIVERSITI BRUNEI DARUSSA...

1. A method of detecting and quantifying target DNA from a biological sample comprising:subjecting the biological sample to DNA extraction and subjecting the obtained DNA sequence to amplification using one or more primers for amplification of target DNA by loop-mediated isothermal amplification (LAMP) method, wherein the one or more primers are selected from a group of twelve primers based on specificity for the target DNA, wherein the group includes a first group of six primers for a target DNA of Sus scrofa species and a second group of six primers for a target DNA of Bacillus subtilis species;
obtaining DNA amplicons based on the amplification of the target DNA by the LAMP method using the selected one or more primers;
subjecting the obtained DNA amplicons to a 1-10 picogram/mL level electrochemiluminescence detection technique by binding the obtained DNA amplicons in one of at least two reaction cells containing a luminophore [Ru(bpy)3]Cl2on a carbon electrode surface in an aqueous buffer solution;
adding electrochemiluminescence reaction triggering reagent to the reaction cells to obtain a mixture of the DNA amplicons, luminophore [Ru(bpy)3]Cl2, aqueous buffer solution, and electrochemiluminescence reaction triggering reagent; and
comparing difference between intensities of light transmitted from the reaction cells to detect and quantify the target DNA, wherein a quantity of the target DNA is based on quantitation of difference between the intensities, wherein intensity of light transmitted from the reaction cell with presence target DNA is less than intensity of light transmitted from a reaction cell with absence of the target DNA.
US Pat. No. 10,888,060

HEMP PLANT NAMED ‘KIRSCHE’

1. A seed, plant, plant part, or plant cell of a hemp plant variety designated ‘KIRSCHE’, wherein seed of the variety has been deposited under NCMA No. 202005042.
US Pat. No. 10,888,830

METHODS AND DEVICES BASED UPON A NOVEL FORM OF NUCLEIC ACID DUPLEX ON A SURFACE

Genomics USA, Inc., Roun...

1. A method for identifying a nucleotide sequence to which a nucleotide-binding protein binds comprising:contacting the biomolecular hybridization device with a nucleotide-binding protein under conditions that permit binding; wherein the biomolecular hybridization device comprises:
a substrate having a surface of functional groups permanently and covalently attached thereto;
an adsorbed monolayer of unmodified, single-stranded oligonucleotides all of which are 10 to about 24 bases in length as a saturated film of constrained oligonucleotides on the surface via direct non-covalent phosphate-surface adsorptive contact of substantially all phosphate groups of each oligonucleotide; wherein each constrained oligonucleotide base plane is presented from the surface in a manner effective to dissociably hybridize to a complementary single-stranded nucleic acid with asymmetric, non-helical base pairing without alteration of the oligonucleotide base plane presentation and without oligonucleotide phosphate group dissociation from the surface; wherein the hybridized oligonucleotides are fixed into an asymmetric, non-helical duplex; and
a single-stranded nucleic acid reversibly hybridized to at least one of said single-stranded oligonucleotides as a non-helical duplex of 10 to about 24 base pairs long adsorbed to the surface;
eluting formed duplex-protein complex(es) from the surface with a salt solution with an ionic strength of an aqueous solution of from about 1 M to about 5 M NaCl; and
sequencing at least one strand of the eluted nucleic acid duplex.
US Pat. No. 10,889,855

DETECTION OF NUCLEIC ACID MOLECULES

miRdetect GmbH, Bremen (...

1. A method of determining the level of a target nucleic acid in a biological sample, wherein the target nucleic acid is DNA obtained from the biological sample or cDNA obtained from RNA obtained from the biological sample, the method comprising the steps of:(i) providing a batch A comprising the target nucleic acid;
(ii) providing three or more aliquots of batch A provided in step (i) and performing an independent polymerase chain reaction (PCR) with each of the three or more aliquots in order to amplify the same single target nucleic acid in each of the three or more aliquots, thereby providing three or more batches B comprising the same amplified -target nucleic acid; and
(iii) mixing equal amounts of the three or more batches B, thereby providing a batch C, and determining the level of the target nucleic acid in batch C by performing a single quantitative real-time PCR (qRT-PCR),
wherein the level determined in step (iii) corresponds to the expression level of the target nucleic acid in the biological sample.
US Pat. No. 10,888,061

INBRED CORN LINE MM66

LIMAGRAIN EUROPE S.A., S...

1. A seed of inbred corn line designated MM66, wherein a representative sample of seed of said line was deposited under ATCC Accession No. PTA-126752.
US Pat. No. 10,888,574

METHOD FOR SUPPRESSING OBESITY, METHOD FOR TREATING OBESITY, AND METHOD FOR PROMOTING GENE EXPRESSION

KINJIRUSHI CO.. LTD., Na...

1. A method for suppressing obesity, the method comprising orally administering to a human subject in need thereof a composition:wherein the composition comprises an isosaponarin and at least one different additive selected from a group consisting of an excipient, a disintegrator, a binder, an antioxidant, a coating agent, a coloring agent, a corrigent, a surfactant, and a plasticizer, and
a final concentration of the isosaponarin is set to 10 ?mol/L in the step of administrating the composition to the human subject.
US Pat. No. 10,888,831

METHOD OF DISTRIBUTING DISCRETE POLYMER NETWORKS

LIFE TECHNOLOGIES CORPORA...

1. A method of forming a color-activated polymer network, the method comprising:preparing a hydrogel discrete polymer network to include halide or amine terminal groups;
reacting the hydrogel discrete polymer network with a dye having amine, hydrizide, or N-hydroxysuccinimide functionality;
rinsing excess dye from the color-activated polymer network;
mixing a plurality of nucleic acid polymer networks with a plurality of the color-activated polymer network to form a dispersion;
applying the dispersion to an array of wells, the nucleic acid polymer networks selectively depositing into wells of the array of wells; and
rinsing the array of wells to selectively remove the plurality of the color-activated polymer network.
US Pat. No. 10,889,856

HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS

BioFire Diagnostics, LLC,...

1. A method of detecting nucleic acids in a sample, comprising the steps of(a) providing a container having
a plurality of fluidly connected reaction chambers including a first-stage amplification zone and a plurality of second-stage amplification chambers, each of the second-stage reaction chambers containing a primer pair configured to amplify a different target nucleic acid that may be present in the sample, and
one or more sealable ports fluidly connected to the reaction chambers, the sealable ports providing the only access from an exterior of the container to reaction blisters,
(b) introducing the sample into the container via a first of the sealable ports, and sealing the first port subsequent to introducing the sample into the container,
(c) mixing the nucleic acids in the sample with PCR reaction components including a plurality of primer pairs configured for amplifying the targets,
(d) thermal cycling the nucleic acids in the first-stage amplification zone to create a first-stage amplification mixture,
(e) moving a portion of the first-stage amplification mixture to each of the second-stage amplification chambers,
(f) thermal cycling the nucleic acids in the second-stage reaction chambers to generate second-stage amplification products, and
(g) detecting which of the second-stage reaction chambers contain second-stage amplification products, wherein the detecting step includes detecting fluorescence emission from a fluorescent dye in the second-stage reaction chambers.
US Pat. No. 10,888,062

MAIZE HYBRID X13N259

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X13N259, representative seed produced by crossing a first plant of variety PH47GA with a second plant of variety PH47CK, wherein representative seed of the varieties PH47GA and PH47CK have been deposited under NCMA Accession Number 202004020 and ATCC Accession Number PTA-126662, respectively.
US Pat. No. 10,888,575

COMBINATION COMPRISING ZIDOVUDINE AND A CARBAPENEM

HELPERBY THERAPEUTICS LIM...

1. A combination comprising zidovudine or a pharmaceutically acceptable salt and/or solvate thereof and a carbapenem or a pharmaceutically acceptable salt and/or solvate thereof, wherein the combination optionally further comprises at least one polymyxin selected from polymyxin B or polymyxin E, or at least one pharmaceutically acceptable salt and/or solvate thereof.
US Pat. No. 10,888,063

SOYBEAN VARIETY 01072800

Monsanto Technology LLC, ...

1. A plant of soybean variety 01072800, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-126477.
US Pat. No. 10,888,576

COMPOSITION OF HMB AND ATP AND METHODS OF USE

Metabolic Technologies, I...

1. A method for increasing the strength of a human in need thereof comprising the steps of administering to said human a synergistic combination of from about 0.5 to about 30 g of ?-hydroxy-?-methylbutyric acid (HMB) and from about 10 mg to about 80 g ATP, wherein upon said administration of HMB and adenosine triphosphate (ATP) to the human, said strength is increased.
US Pat. No. 10,889,858

METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTS

GUARDANT HEALTH, INC., R...

1. A method for analyzing sequencing reads of double-stranded cell-free deoxyribonucleic acid (cfDNA) molecules from a sample of a subject, comprising:(a) tagging a plurality of double-stranded cfDNA molecules from a population of double-stranded cfDNA molecules from the sample with a set of library adaptors comprising a plurality of molecular barcodes to generate tagged parent polynucleotides,
wherein the tagging comprises ligating a plurality of library adaptors from the set of library adaptors to the plurality of double-stranded cfDNA molecules from the population using more than a 10× molar excess of library adaptors as compared to the double-stranded cfDNA molecules of the population;
wherein the tagging produces at least 20% of the double-stranded cfDNA molecules of the populations having library adaptors ligated to both ends of a molecule of the double-stranded cfDNA molecules;
(b) amplifying a plurality of the tagged parent polynucleotides to produce progeny polynucleotides;
(c) sequencing a plurality of the progeny polynucleotides to produce a set of sequencing reads; and
(d) determining, based at least on sequence information from the molecular barcodes, individual double-stranded cfDNA molecules from among the tagged parent polynucleotides for which either (1) both a Watson strand and a Crick strand of the individual double-stranded cfDNA molecule are detected or (2) only one of a Watson strand or a Crick strand of the individual double-stranded cfDNA molecule is detected from a plurality of sequencing reads from the set of sequencing reads.
US Pat. No. 10,888,064

METHODS AND COMPOSITIONS RELATED TO IMPROVED NITROGEN UTILIZATION EFFICIENCY IN TOBACCO

Altria Client Services LL...

1. A method of producing a tobacco plant comprising an enhanced nitrogen utilization efficiency (NUE) trait comprising:a. providing a first population of tobacco plants comprising an enhanced NUE trait;
b. genotyping said first population of tobacco plants via a molecular assay for the presence of one or more molecular markers located within 10 cM of a SNP marker comprising the sequence of SEQ ID NO:57 and having a polymorphic position 147 with an allele of T associated with an enhanced NUE trait;
c. selecting a tobacco plant comprising said one or more molecular markers;
d. crossing said tobacco plant selected in step (c) with a second tobacco plant; and
e. obtaining progeny seed from the cross of step (d) wherein a plant grown from said progeny seed comprises said enhanced NUE trait and said one or more molecular markers.
US Pat. No. 10,888,577

MIRNA BIOMARKERS FOR CARTILAGE DEGENERATION

UNIVERSITY HEALTH NETWORK...

1. A method of reducing severity of osteoarthritis in a joint of a subject in need thereof, the joint selected from knee and facet, the method comprising administering to the subject an antisense oligonucleotide having at least 95% sequence identity to any one of SEQ ID NO: 3 or SEQ ID NO: 4.
US Pat. No. 10,889,859

TRANSPOSITION OF NATIVE CHROMATIN FOR PERSONAL EPIGENOMICS

The Board of Trustees of ...

1. A method for analyzing chromatin, comprising:(a) isolating a plurality of cell nuclei from a cell sample;
(b) contacting chromatin from a nucleus of said plurality of cell nuclei with an insertional enzyme complex to produce a plurality of tagged fragments of genomic deoxyribonucleic acid (DNA) in said nucleus;
(c) providing said nucleus into a nucleic acid reaction mixture, wherein said nucleic acid reaction mixture comprises at most a single nucleus; and
(d) performing one or more nucleic acid reactions on a tagged fragment of said plurality of tagged fragments.
US Pat. No. 10,889,091

LAMINATED GLASS

ZEON CORPORATION, Tokyo ...

1. A laminated glass which is prepared by inserting a resin intermediate film between glass plates and adhering the glass plates to integrate them,wherein the laminated glass has a bending deflection at 90° C. of 7.3 N/mm2 or higher and a weight per unit area of 7.5 kg/m2 or less,
wherein the bending deflection is measured by bonding two glass plates each having a length of 100 mm, a width of 20 mm and a thickness of 0.5 mm to 1.5 mm through the resin intermediate film to form a test piece, subjecting the test piece to a 4-point bending test in accordance with JIS R1602 method, and calculating the bending deflection by equation (1):
Bending deflection=(27/(5×L3))×t3E  (1)
wherein L is a distance between supporting rolls of the 4-point bending test in mm, t is a thickness of the test piece in mm, and E is an elastic modulus of the test piece measured by the 4-point bending test in MPa;
wherein the resin intermediate film:
contains a mixture of:
a modified hydrogenated block copolymer [E] obtained by introducing an alkoxysilyl group into a hydrogenated block copolymer [D], and
a hydrogenated block copolymer [D?] having a higher storage elastic modulus at a temperature of 90° C. than that of the hydrogenated block copolymer [D]; or
is a multilayer comprising:
a first layer including the modified hydrogenated block copolymer [E], and
a second layer including the hydrogenated block copolymer [D] and/or the hydrogenated block copolymer [D?], wherein the first layer and the second layer are alternately laminated,
wherein storage elastic moduli measured via dynamic viscoelasticity of the resin intermediate film are 5×108 Pa or lower at a temperature of ?20° C. and 3×107 Pa or higher at a temperature of 90° C.,
wherein the hydrogenated block copolymer [D] is obtained by hydrogenating 90% or more of carbon-carbon unsaturated bonds on a main chain and side chains and carbon-carbon unsaturated bonds on an aromatic ring in a block copolymer [C] which contains at least two polymer blocks [A] containing 95 wt % or more of a structural unit derived from an aromatic vinyl compound and at least one polymer block [B] containing 80 wt % or more of a structural unit derived from an acyclic conjugated diene compound, wherein a ratio (wA:wB) of a weight fraction (wA) of the polymer block [A] to a weight fraction (wB) of the polymer block [B] is 40:60 to 60:40,
wherein the hydrogenated block copolymer [D?] is obtained by hydrogenating 90% or more of carbon-carbon unsaturated bonds on a main chain and side chains and carbon-carbon unsaturated bonds on an aromatic ring in a block copolymer [C?] which contains at least two polymer blocks [A?] containing 95 wt % or more of a structural unit derived from an aromatic vinyl compound and at least one polymer block [B?] containing 80 wt % or more of a structural unit derived from an acyclic conjugated diene compound, wherein a ratio (wA?:wB?) of a weight fraction (wA?) of the polymer block [A?] to a weight fraction (wB?) of the polymer block [B?] is 50:50 to 70:30,
wherein the modified hydrogenated block copolymer [E] includes the alkoxysilyl group introduced into the hydrogenated block copolymer [D] in an amount of 0.1 to 10 parts by weight of the alkoxysilyl group based on 100 parts of the hydrogenated block copolymer [D],
wherein a content of the modified hydrogenated block copolymer [E] in the resin intermediate film is 26 wt % or more, and
wherein a ratio (tR/t) of a thickness of the resin intermediate film (tR) in the laminated glass to a total thickness of the laminated glass (t) 20 to 80%.
US Pat. No. 10,889,860

COMPOSITIONS AND METHODS FOR SINGLE G-LEVEL HLA TYPING

GEORGETOWN UNIVERSITY, W...

1. A kit, comprisinga first set of oligonucleotide primers for polymerase chain reaction (PCR) amplification of at least one human leukocyte antigen (HLA) class I locus, at least one HLA class II locus, or both at least one HLA class I locus and at least one HLA class II locus of a subject; and
a second set of oligonucleotide primers for performing one-step DNA sequencing of at least one amplicon prepared using the first set of oligonucleotide primers, wherein the at least one amplicon comprises the at least one HLA class I locus, the at least one HLA class II locus, or both the at least one HLA class I locus and the at least one HLA class II locus of the subject,
wherein: each oligonucleotide primer of the first set of oligonucleotide primers comprises a non-nucleotide detectable tag or marker;
the first set of oligonucleotide primers comprises at least two primers comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 5, 6, 9-15, and 19-29; and
the second set of oligonucleotide primers comprises at least two primers comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 32, 33, 37, 39, 40, 42-48, and 50-54.
US Pat. No. 10,888,836

EXTRACTION OF TARGET MATERIALS USING CZTS SORBENT

CHEMICAL AND METAL TECHNO...

1. A method of extracting a target material from a medium, the method comprising:contacting a copper zinc tin sulfur (CZTS) sorbent with the target material in the medium comprising the target material to form a used CZTS sorbent that comprises the target material.
US Pat. No. 10,889,861

SYSTEMS AND METHODS FOR OBTAINING BIOLOGICAL MOLECULES FROM A SAMPLE

The Translational Genomic...

1. A method of determining the sex of an in utero fetus, the method comprising the steps of:obtaining a sample of biofluid from a pregnant mother, wherein the biofluid is selected from the group consisting of: blood, plasma, serum, urine, and cerebrospinal fluid, and wherein the sample is stored on a sample collection apparatus, the sample collection apparatus comprises cellulose paper on which the biofluid is placed to dry, and the cellulose paper has not been treated with any chemical stabilizers of nucleic acids;
extracting nucleic acids from the sample, wherein the nucleic acids are RNA;
sequencing the extracted nucleic acids to generate sequence data, wherein the RNA is sequenced with RNA-Seq; and
analyzing the sequence data to determine the sex of the in utero fetus, wherein the in utero fetus is male if expression of Y chromosome genes is similar to or greater than expression of X chromosome genes in the sample, wherein analyzing the sequence data comprises:
processing sequencing reads to remove information related to barcodes and adapters;
aligning the sequencing reads to reference sequences;
quantifying the aligned sequencing reads to generate a numerical estimate of each gene's expression or counts; and
determining total counts from Y chromosome genes and total counts from X chromosome genes.
US Pat. No. 10,888,580

HIGH ELASTICITY HYALURONAN COMPOSITIONS AND METHODS OF USE THEREOF

Matrix Biology Institute,...

1. A method for alleviating pain and discomfort associated with wound healing in a subject in need thereof, the method comprising administering to said subject a composition comprising hyaluronan, wherein:the hyaluronan is present in said composition at a concentration of greater than about 30 mg/mL;
the hyaluronan has an average molecular weight of between about 1 and about 2 million;
the hyaluronan is not cross-linked and/or is free of chemical modifications; and
wherein the composition is free of polyol and a local anesthetic, thereby alleviating said pain and discomfort associated with wound healing.
US Pat. No. 10,888,581

CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF

THE REGENTS OF THE UNIVER...

1. One or more isolated nucleic acids comprising a nucleotide sequence(s) encoding a heterodimeric chimeric antigen receptor (CAR) comprising:a first polypeptide comprising a first member of a dimerization pair, a first transmembrane domain, and an intracellular signaling domain; and
a second polypeptide comprising an antigen-binding domain that comprises a single chain antibody variable region that specifically binds to CD19 or an antigen expressed by an immune cell, a second member of the dimerization pair, and a second transmembrane domain;
wherein the first and second members of the dimerization pair are located intracellularly when the first and second peptides are expressed in a host immune cell and
wherein the first polypeptide does not comprise an antigen-binding domain and the second polypeptide does not comprise an intracellular signaling domain capable of inducing immune activation,
wherein a dimerizing agent dimerizes the first and second polypeptides to form the heterodimeric CAR when the first and second polypeptides are expressed by the host immune cell with the dimerizing agent bound between the dimerization pair members of the first and second polypeptides, and wherein activation of the immune cell by the formed heterodimeric CAR binding CD19 or said antigen is increased as compared to activation of the immune cell in the absence of the dimerizing agent.
US Pat. No. 10,889,863

FRET-BASED ANALYTES DETECTION AND RELATED METHODS AND SYSTEMS

CALIFORNIA INSTITUTE OF T...

1. A kit to detect at least one polynucleotide analyte in a sample, the kit comprising:at least one primer pair formed by a forward primer attaching a first FRET chromophore and a reverse primer attaching a second FRET chromophore;
wherein the first FRET chromophore and the second FRET chromophore are selected to provide an energy transfer from one to another when located at a Forster distance one with respect to the another thus forming a FRET donor-acceptor chromophore pair;
the forward primer has a sequence specific for a first single strand target polynucleotide within the at least one polynucleotide analyte;
the reverse primer has a sequence specific for a second single strand target polynucleotide within the at least one polynucleotide analyte;
the first single strand target polynucleotide and the second single strand target polynucleotide are located within the at least one polynucleotide analyte so that upon specific binding of the forward primer with the first target polynucleotide and specific binding of the reverse primer with the second target polynucleotide, the first FRET chromophore and the second FRET chromophore are located at a distance up to four times the Forster distance one with respect to the other; and
wherein at least one or both the first FRET chromophore and the second FRET chromophore is attached within 10 bases of a 5? end of at least one or both the forward primer and the reverse primer and the forward primer is not complementary to the reverse primer.
US Pat. No. 10,888,582

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 8, thereby inducing a T cell response to the cancer,wherein said cancer is selected from colorectal cancer, non-Hodgkin lymphoma, ovarian cancer, renal cell carcinoma, and non-small cell lung cancer.
US Pat. No. 10,889,864

NON-CODING RNAS AND USES THEREOF

THE REGENTS OF THE UNIVER...

1. A method of detecting a non-coding RNA in a subject, comprising(a) contacting a biological sample comprising a prostate cancer cell or tissue from a subject with a gene expression detection assay, wherein said gene expression detection assay comprises a gene expression informative reagent for identification of the level of expression of SEQ ID NOs: 1710, 1277, and 614; and
(b) detecting the level of expression of said non-coding in said sample using an in vitro assay.
US Pat. No. 10,888,583

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that are capable of killing cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 9,wherein said cancer is selected from the group consisting of chronic lymphocytic leukemia, colorectal cancer, non-Hodgkin lymphoma, non-small cell lung cancer, esophageal cancer, and small cell lung cancer.
US Pat. No. 10,888,840

MATERIAL FOR REMOVING ACTIVATED LEUKOCYTE-ACTIVATED PLATELET COMPLEX

TORAY INDUSTRIES, INC., ...

1. A material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound,wherein an extending length ratio of said surface is 4 to 7.
US Pat. No. 10,888,584

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that are capable of killing cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 29, wherein said cancer is selected from the group consisting of acute myeloid leukemia, chronic lymphocytic leukemia, glioblastoma, head and neck squamous cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, and uterine endometrial cancer.
US Pat. No. 10,888,841

AFFINITY CHROMATOGRAPHY CARRIER AND METHOD FOR PURIFYING BIOLOGICAL SUBSTANCE

FUJIFILM Corporation, To...

1. An affinity chromatography carrier, comprising:a substrate;
a hydrophilic polymer; and
an affinity ligand, wherein
the substrate is comprised of at least one selected from the group consisting of agarose and crosslinked agarose,
the hydrophilic polymer is at least one selected from the group consisting of hydrophilic polysaccharides,
the substrate is coated with the hydrophilic polymer,
the affinity ligand is at least one selected from the group consisting of an antibody-binding protein and an antibody-binding polypeptide,
a carboxy group is introduced into the affinity chromatography carrier,
the amount of the carboxy group introduced is 15 mmol/L-gel to 60 mmol/L-gel in terms of ion exchange capacity, and
the coating amount of the hydrophilic polymer is from 3 to 240 mg/g-dry gel.
US Pat. No. 10,889,866

SPLICE VARIANTS ASSOCIATED WITH NEOMORPHIC SF3B1 MUTANTS

1. A method of treating a patient having a neoplastic disorder, comprising administering an SF3B1-modulating compound to the patient, wherein a sample from the patient has been tested to detect expression of five splice variants comprising SEQ ID NO:41, SEQ ID NO:61, SEQ ID NO:101, SEQ ID NO:160, and SEQ ID NO:230, and the sample expresses the five splice variants.
US Pat. No. 10,888,585

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that are capable of killing cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 30, wherein said cancer is selected from the group consisting of chronic lymphocytic leukemia, hepatocellular carcinoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, and uterine endometrial cancer.
US Pat. No. 10,888,842

SOLID CATALYST FOR MANUFACTURING FATTY ACID METHYL OR ETHYL ESTER AND METHOD FOR MANUFACTURING FATTY ACID METHYL OR ETHYL ESTER USING THE SAME

Seong Min Yoo, Gwacheon-...

1. A solid catalyst with a non-crystalline porous structure that is adapted for converting oil containing a fatty acid to fatty acid methyl or ethyl ester, wherein said solid catalyst is prepared by (i) mixing an oxide and/or oxides of manganese as active catalytic material and soda lime glass as carrier that consists of SiO2 as the main component and an impurity mixture comprising Na2O, CaO, Al2O3, K2O, SO3, MgO, Fe2O3, and TiO2 to obtain a mixture, (ii) molding the mixture, and (iii) sintering the molded mixture to produce said solid catalyst having a non-crystalline porous structure, wherein said solid catalysts comprises:73-76 wt % of SiO2,
12-15 wt % of Na2O,
8-11 wt % of CaO,
2 wt % or less of Al2O3,
1 wt % or less of K2O,
0.5 wt % or less of SO3,
0.5 wt % or less of MgO,
1 wt % or less of Fe2O3, and
0.5 wt % or less of TiO2.
US Pat. No. 10,889,867

SYNTHETIC NUCLEIC ACID CONTROL MOLECULES

1. A method of characterizing a DNA test sample, comprising:a) providing a run control composition comprising:
i) a first synthetic DNA fragment comprising a methylation footprint nucleotide sequence of a human gene, the methylation footprint nucleotide sequence in said first synthetic DNA fragment comprising a pattern of cytosines, wherein each of the cytosines within the methylation footprint nucleotide sequence comprises a 5-methyl;
ii) a second synthetic DNA fragment comprising the methylation footprint nucleotide sequence of the human gene, the methylation footprint nucleotide sequence in the second synthetic DNA fragment comprising the same number and pattern of cytosines as the methylation footprint nucleotide sequence in the first synthetic DNA fragment, wherein none of the cytosines within the methylation footprint nucleotide sequence in the second synthetic DNA fragment comprises a 5-methyl, and
iii) fish DNA;
wherein a ratio of the of the number of copies of the first synthetic DNA fragment to the number of copies of the second synthetic DNA fragment in the run control composition produces a run control expected result when assayed in a methylation assay;
b) providing a DNA test sample isolated from a human subject;
c) applying the methylation assay to the run control composition to produce run control experimental data;
d) applying the methylation assay to the DNA test sample to produce test sample experimental data; and
e) classifying the test sample experimental data as valid if the run control experimental data are within a pre-defined acceptable range relative to the run control expected result.
US Pat. No. 10,888,586

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that are capable of killing cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 31, wherein said cancer is selected from the group consisting of gastric cancer, hepatocellular carcinoma, non-Hodgkin lymphoma, non-small cell lung cancer, renal cell carcinoma, and pancreatic cancer.
US Pat. No. 10,889,868

EXOSOMAL BIOMARKERS DIAGNOSTIC OF TUBERCULOSIS

University of Notre Dame ...

1. A method for identifying an active M. tuberculosis infection in a subject comprising:isolating extracellular vesicles from bodily fluid of a subject, wherein the extracellular vesicles contain a plurality of RNA;
extracting at least a portion of the RNA from the extracellular vesicle; and
analyzing the RNA for the presence of one or more RNA that are indicative of an active M. tuberculosis infection; wherein the RNA that are indicative of an active M. tuberculosis infection are selected from the group consisting of RV1821, RV1842c, RV3894c, RV0453, RV1629, RV0170, RV0668, RV0740, RV0288, RV1344, RV0968, RV1942c, RV0664, RV0190, RV1757c, RV1369c, RV3809c, RV3533, RV0243, RV1101c, RV2796, and RV2024c, thereby determining the presence or absence of an active M. tuberculosis infection in the subject.
US Pat. No. 10,888,587

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a composition comprising a population of activated T cells that kill cancer cells in the patient that present a peptide, wherein said peptide consists of the amino acid sequence of SEQ ID NO: 119, wherein said cancer is selected from the group consisting of ovarian cancer, non-small cell lung cancer, small cell lung cancer, kidney cancer, brain cancer, colon or rectum cancer, stomach cancer, liver cancer, pancreatic cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma, melanoma, esophageal cancer, urinary bladder cancer, uterine cancer, gallbladder cancer, and bile duct cancer.
US Pat. No. 10,889,613

SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS

Massachusetts Institute o...

1. A peptide synthesizer system, comprising:a first reagent reservoir connected to a first channel;
a second reagent reservoir connected to a second channel;
a pre-heat channel downstream of and fluidically connected to the first channel and the second channel;
a reactor downstream of and connected to the pre-heat channel;
a heat exchanger in thermal communication with the pre-heat channel and the reactor;
a waste channel downstream of and connected to the reactor; and
a UV detector in optical communication with the waste channel.
US Pat. No. 10,889,869

COMPOSITIONS AND METHODS FOR DETECTION OF HERPES SIMPLEX VIRUS 1 AND 2

Roche Molecular Systems, ...

1. A kit for detecting a nucleic acid of HSV-1 and/or HSV-2 comprising:a plurality of sets of HSV-1 and HSV-2 primers specific for amplification of an HSV-1 Pol and an HSV-1 TK gene targets, and an HSV-2 TK and an HSV-2 gB gene targets; and
a plurality of detectable HSV-1 and HSV-2 probes specific for detection of an HSV-1 Pol and an HSV-1 TK amplification products, and an HSV-2 TK and an HSV-2 gB amplification products;
wherein the primer set for amplification of the HSV-1 Pol gene target comprise nucleic acid sequences of SEQ ID NOs: 1 and 2 or a complement thereof, the primer set for amplification of the HSV-1 TK gene target comprise nucleic acid sequences of SEQ ID NOs: 4 and 5 or a complement thereof, the primer set for amplification of the HSV-2 TK gene target comprise nucleic acid sequences of SEQ ID NOs: 7 and 8 or a complement thereof, the primer set for amplification of the HSV-2 gB gene target comprise nucleic acid sequences of SEQ ID NOs: 10 and 11 or a complement thereof, and
wherein the detectable of HSV-1 probe for detection of the HSV-1 Pol amplification product comprises the nucleic acid sequence of SEQ ID NO: 3 or a complement thereof, the detectable of HSV-1 probe for detection of the HSV-1 TK amplification product comprises the nucleic acid sequence of SEQ ID NO: 6 or a complement thereof, the detectable of HSV-2 probe for detection of the HSV-2 TK amplification product comprises the nucleic acid sequence of SEQ ID NO: 9 or a complement thereof, the detectable of HSV-2 probe for detection of the HSV-2 gB amplification product comprises the nucleic acid sequence of SEQ ID NO: 12 or a complement thereof;
wherein each probe of said plurality of detectable HSV-1 and HSV-2 probes comprises a donor fluorescent moiety and a corresponding acceptor fluorescent moiety.
US Pat. No. 10,888,588

DIRECTED CARDIOMYOCYTE DIFFERENTIATION AND VENTRICULAR SPECIFICATION OF STEM CELLS

ICAHN SCHOOL OF MEDICINE ...

1. A method of generating a cardiogenic embryoid body comprising at least one ventricular-like cardiomyocyte, said method comprising incubating a non-terminally differentiated human cell in suspension under serum-free, feeder-free culture conditions, wherein said incubating comprises the following sequential steps:(a) culturing the non-terminally differentiated human cell for 24 to 72 hours in a suspension consisting essentially of basement membrane preparation extracted from Engelbreth-Holm-Swarm mouse sarcoma, a culture medium for cells that have not terminally differentiated, bone morphogenetic protein 4 (BMP4), and Rho kinase inhibitor;
(b) incubating the culture for 3 to 5 days in a suspension consisting essentially of the basement membrane preparation, a serum-free medium formulated to support the growth of human hematopoietic progenitor cells, ascorbic acid, L-alanyl-L-glutamine, BMP4, and activin-A; and
(c) growing the culture for at least four days in a suspension consisting essentially of the basement membrane preparation, the serum-free medium, ascorbic acid, L-alanyl-L-glutamine, BMP4, activin-A, and Inhibitor of Wnt Response 1 (IWR-1) to generate a culture of cardiomyocytes with a yield of at least 90% ventricular-like cardiomyocytes.
US Pat. No. 10,889,614

SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS

Massachusetts Institute o...

1. A process for adding amino acid residues to peptides, comprising:providing a plurality of peptides comprising protection groups, each peptide immobilized on a solid support;
exposing a deprotection reagent to the immobilized peptides to remove the protection groups from at least a portion of the immobilized peptides;
removing at least a portion of the deprotection reagent;
exposing a heated stream comprising activated amino acids to the immobilized peptides such that at least a portion of the activated amino acids are bonded to the immobilized peptides to form newly-bonded amino acid residues; and
removing at least a portion of activated amino acids that do not bond to the immobilized peptides;
wherein an amino acid residue is added to at least about 99% of the immobilized peptides during the amino acids exposing step; and
wherein the total amount of time taken to perform the combination of all of the deprotection reagent exposing step, the deprotection reagent removal step, the activated amino acid exposing step, and the activated amino acid removal step is from about 10 seconds to about 5 minutes.
US Pat. No. 10,889,870

STEEL COMPONENT, GEAR COMPONENT, AND PRODUCING METHOD FOR STEEL COMPONENT

AISIN AW CO., LTD., Anjo...

1. A steel component that is made of starting material steel comprising, as chemical components:C (carbon): 0.05 mass % or more to 0.30 mass % or less;
Si (silicon): 1.0 mass % or more to 3.0 mass % or less;
Mn (manganese): 0.1 mass % or more to 3.0 mass % or less;
P (phosphorus): 0.03 mass % or less;
S (sulfur): 0.001 mass % or more to 0.150 mass % or less;
Cr (chromium): 0.01 mass % or more to 0.20 mass % or less;
Al (aluminum): 0.01 mass % or more to 0.05 mass % or less;
N (nitrogen): 0.003 mass % or more to 0.030 mass % or less; and
Fe, trace amounts of other alloy components as optional components, and unavoidable impurities: a balance, wherein
a concentration of C in a surface layer of the steel component is 0.85 mass % or more to 1.2 mass % or less that is higher than a concentration of C in the starting material steel,
the surface layer has a volume ratio of a retained-austenite structure of higher than 0% and lower than 10%, a remainder of the surface layer is a martensitic structure, and an area fraction of grain boundary carbides in the surface layer is lower than 2%, and
a layer inside the surface layer has a volume ratio of a retained-austenite structure higher than the volume ratio of the retained-austenite structure in the surface layer, and in the layer inside the surface layer, a remainder is a martensitic structure.
US Pat. No. 10,888,589

MODULATION OF STEM CELLS USING ZINC FINGER PROTEINS

Sangamo Therapeutics, Inc...

1. An isolated stem cell comprising a homeobox protein B4 (HOXB4) gene or octamer-binding transcription factor 4 (OCT-4) gene, wherein expression of the HOXB4 or OCT-4-gene is modified by an artificial fusion protein comprising(i) an engineered C2H2 zinc finger protein (ZFP) DNA binding domain that binds to a target site in the HOXB4 or OCT-4 gene, the ZFP comprising a ZFP comprising 3 zinc finger domains ordered F1 to F3, each zinc finger domain comprising a recognition helix region as follows:
F1: RSDHLAR (SEQ ID NO:21);
F2: RSDELQR (SEQ ID NO:22);
F3: RSDERKR (SEQ ID NO:23)
for binding to the HOXB4 gene or a ZFP comprising 3 zinc finger domains ordered F1 to F3, each zinc finger domain comprising a recognition helix region as follows:
F1: RSDHLAR (SEQ ID NO:2);
F2: TSGSLTR (SEQ ID NO:3); and
F3: RSDNLAR (SEQ ID NO:4) for binding to OCT-4; and
(ii) a functional domain comprising a VP16 or p65 transcriptional activation domain or a KRAB repression domain.
US Pat. No. 10,888,846

MANGANESE-DOPED NICKEL-METHANATION CATALYSTS

CLARIANT PRODUKTE (DEUTSC...

1. A catalyst for the methanation of carbon monoxide and/or carbon dioxide, comprising aluminum oxide, a Ni active mass, and Mn, and having a Ni/Mn molar ratio in the range of 4.0-6.5 and a Al/Ni molar ratio in the range of 0.5 to 1.5.
US Pat. No. 10,889,615

MUTATED IMMUNOGLOBULIN-BINDING POLYPEPTIDES

1. An Fc-binding polypeptide comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), wherein the polypeptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO:51 and SEQ ID NO:52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NOs:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine, and wherein when the polypeptide comprises SEQ ID NO:3 or SEQ ID NO:22, the asparagine residue is not mutated to histidine.
US Pat. No. 10,888,590

MEDICATED PROPOLIS OIL COMPOSITION

MatrixMed Inc., New York...

1. A medicated oil composition comprisingpropolis, about 1-40% by weight,
a lipophobic carrier, wherein said carrier includes but is not limited to a fatty acid coconut oil, about 30-90% by weight,
an analgesic, about 0.1-10% by weight,
a surfactant, about 0.25-20% by weight, and
a lipophilic diluent, about 5-50% by weight.
US Pat. No. 10,889,872

TOOL STEEL ARTICLES FROM ADDITIVE MANUFACTURING

KENNAMETAL INC., Latrobe...

1. A method of forming a tooling article comprising:consolidating powder alloy into the tooling article via an additive manufacturing technique comprising sintering or melting; and
heat treating the tooling article to provide the tooling article hardness of 35 to 65 HRC and a tensile strength of 1200-2200 MPa, wherein the tooling article is formed of an alloy composition comprising 0.2-2 weight percent carbon, 0-1 weight percent manganese, 0-1.5 weight percent silicon, 0-0.3 weight percent nickel, 0-15 weight percent cobalt, at least two of chromium, molybdenum, tungsten and vanadium in a combined amount of 5-25 weight percent and the balance iron.
US Pat. No. 10,888,591

NANO-VESICLES DERIVED FROM GENUS MICROCOCCUS BACTERIA AND USE THEREOF

MD HEALTHCARE INC., Seou...

1. A method of suppressing inflammation in a mammal, the method comprising treating the mammal by administering a composition comprising an effective amount of extracellular vesicles isolated from Micrococcus luteus and measuring the suppression of inflammation.
US Pat. No. 10,888,848

CATALYTIC CRACKING CATALYST AND PREPARATION THEREOF

RESEARCH INSTITUTE OF PET...

1. A catalytic cracking catalyst, comprising from about 10% to about 50% by weight, on a dry basis, of a rare earth modified Y-type molecular sieve, about 2% to about 40% by weight, on a dry basis, of an additive-containing alumina, and about 10% to about 80% by weight, on a dry basis, of clay; wherein the additive-containing alumina comprises, on a dry basis and based on the weight of the additive-containing alumina, about 60% to about 99.5% by weight of alumina and about 0.5% to about 40% by weight of an additive that is one or more selected from the group consisting of compounds containing alkaline earth metal, lanthanide metal, silicon, gallium, boron and/or phosphorus; the rare earth modified Y-type molecular sieve has a rare earth oxide content of about 4% to about 12% by weight, a phosphorus content of about 0% to about 10% by weight on the basis of P2O5, a sodium oxide content of no more than about 1.0% by weight, a total pore volume of about 0.36 mL/g to about 0.48 mL/g, a percentage of the pore volume of secondary pores having a pore size of 2-100 nm to the total pore volume of the modified Y-type molecular sieve of about 20% to about 40%, a lattice constant of about 2.440-2.455 nm, a percentage of non-framework aluminum content to the total aluminum content of the modified Y-type molecular sieve of no more than about 10%, a lattice collapse temperature of not lower than about 1060° C., and a ratio of B acid to L acid in the total acid content of the modified Y-type molecular sieve of no less than about 3.5, as determined by pyridine adsorption infrared spectroscopy at 200° C.
US Pat. No. 10,889,617

CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells that selectively recognize cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 19, 20, 23, 24, 25, 26, 27, or 28,wherein the activated T cells are produced by contacting T cells with the peptide loaded onto a human class I MHC molecule expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells,
wherein said cancer is selected from myeloma, lung cancer, kidney cancer, brain cancer, stomach cancer, colon or rectal cancer, liver cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma (MCC), melanoma, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, gall bladder cancer, and bile duct cancer.
US Pat. No. 10,888,592

HAFNIA ALVEI BASED PHARMACEUTICAL AND FOOD COMPOSITIONS FOR INDUCING SATIATION AND PROLONGING SATIETY

TARGEDYS, Rouen (FR) INS...

1. A method of stimulating weight loss in a warm-blooded subject in need thereof, the method comprising administering to the subject an effective amount of Hafnia alvei.
US Pat. No. 10,888,849

BIFUNCTIONAL CATALYST COMPRISING EVENLY DISTRIBUTED PHOSPHOROUS

1. A bifunctional catalyst having a center, a core, an outer surface, and a shell, the core surrounding the center and having a diameter of about 300 ?m, the shell having a width of about 300 ?m, the catalyst comprising a ZSM-5 zeolite, an alumina binder, Zn and P with a zeolite phase and a binder phase, wherein the P is present and is evenly distributed throughout the catalyst, such that the concentration of the P at the center of the catalyst is substantially the same as the concentration of the P at the core of the catalyst, the P has a concentration of 0.1-3 wt % at the core of the catalyst, and the Zn has a concentration above 3 wt % at the core of the catalyst, and wherein the total Zn content in the catalyst is 3-25 wt %, the alumina binder is an alumina binder or an alumina-based binder comprising mixtures of aluminum oxide and aluminum hydroxide and/or silica alumina, and wherein a P/Zn atomic ratio in the catalyst is at least 0.2.
US Pat. No. 10,889,618

D-ENANTIOMERIC PEPTIDES DERIVED FROM D3 AND USE THEREOF

FORSCHUNGSZENTRUM JUELICH...

1. A peptide containing at least one amino acid sequence, wherein the peptide comprises at least 50% D-enantiomeric amino acids and the at least one amino acid sequence is SEQ ID NO: 5 or a homolog thereof with a sequence identity of at least 83%.
US Pat. No. 10,889,874

THICK STEEL PLATE FOR HIGH HEAT INPUT WELDING AND HAVING GREAT HEAT-AFFECTED AREA TOUGHNESS AND MANUFACTURING METHOD THEREFOR

1. A thick steel plate for high heat input welding and having great heat-affected area toughness, comprising a chemical composition in mass percentage:C: 0.05-0.09%,
Si: 0.10-0.30%,
Mn: 1.2-1.6%,
P?0.02%,
S: 0.0015-0.007%,
Ni: 0.2-0.4%,
Ti: 0.005-0.03%,
Mg: 0.005-0.004%,
N: 0.001-0.006%,
Al: 0.004-0.036%,
Ca?0.0032%,
REM?: 0.005%,
Zr?0.003%,
Cr: 0.06-0.2%,
and a balance of Fe and other inevitable impurities;
wherein the chemical composition satisfies the following relationship:
1?Ti/N?6,Mg/Ti?0.017;
the effective S content in steel=S?1.3Mg?0.8Ca?0.34REM?0.35Zr;
the effective S content in steel: 0.0003-0.003%;
the amount of composite inclusion MgO+Ti2O3+MnS in the steel plate, calculated based on areal density, is at a proportion of ?5%.
US Pat. No. 10,888,593

USE OF PECTIN OR PECTIN-RELATED SACCHARIDES TO ENHANCE EFFICACY OF PLANT GROWTH-PROMOTING RHIZOBACTERIA (PGPR) STRAINS FOR PROMOTING GROWTH AND HEALTH IN PLANTS AND ANIMALS

AUBURN UNIVERSITY, Aubur...

11. A method for improving growth or health of a plant, the method comprising: (a) treating the plant, seeds of the plant, or soil surrounding the plant with Bacillus velezensis (BV) and (b) treating the plant, the seeds of the plant, or the soil surrounding the plant with a saccharide comprising pectin or a pectin-related saccharide, wherein the pectin-related saccharide is a heteropolysaccharide comprising D-galacturonate monomers which represent at least 50% of all monomers of the heteropolysaccharide.
US Pat. No. 10,888,850

NOBLE METAL AND BASE METAL DEWAXING CATALYST

ExxonMobil Research and E...

1. A catalyst precursor comprising:at least one noble metal, at least one Group 6 metal, at least one non-noble Group 8-10 base metal and a dispersion agent supported on a support comprising a zeolitic framework structure having a 10-member ring as a largest pore channel,
wherein the catalyst precursor has a molar ratio of the least one non-noble Group 8-10 base metal to the at least one Group 6 metal of about 0.1 to about 10 and a molar ratio of the dispersion agent to the least one Group 8-10 base metal of about 0.5 to about 10.